falseVuzix Corp0001463972--12-312023Q2P12M00P36MP12MP12MP18MP18MP12MP12MP12MP12MP3YP36MP36MP6M0001463972vuzi:StockOptionsTiedToEquityMarketCapitalizationMilestoneMember2022-12-310001463972vuzi:OemProductAndWaveguideSalesMember2023-01-012023-06-3000014639722022-03-022022-03-020001463972us-gaap:EmployeeStockOptionMembervuzi:LongTermIncentivePlan2021Memberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-03-172021-03-170001463972vuzi:PointInTimeMember2023-01-012023-06-300001463972vuzi:OverTimeInputMethodMember2023-01-012023-06-300001463972vuzi:PointInTimeMember2022-01-012022-06-300001463972vuzi:OverTimeInputMethodMember2022-01-012022-06-300001463972vuzi:UkBasedPublicCompanyMember2023-06-300001463972us-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMember2023-04-012023-06-300001463972us-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-06-300001463972us-gaap:AccountsReceivableMember2023-01-012023-06-300001463972us-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMember2022-04-012022-06-300001463972us-gaap:AccountsReceivableMember2022-01-012022-12-310001463972us-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-06-300001463972vuzi:EquityMarketAndOperationalMilestonesTwoMember2023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesThreeMember2023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesSixMember2023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesSevenMember2023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesOneMember2023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesNineMember2023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesFourMember2023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesFiveMember2023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesEightMember2023-06-300001463972vuzi:AtomisticSasMember2022-12-310001463972vuzi:StockOptionTiedToEquityMarketAndOperationalMilestonesMember2023-01-012023-06-300001463972vuzi:EquityMarketCapitalizationTargetsMember2023-01-012023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesTwoMember2023-01-012023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesThreeMember2023-01-012023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesSixMember2023-01-012023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesSevenMember2023-01-012023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesOneMember2023-01-012023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesNineMember2023-01-012023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesFourMember2023-01-012023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesFiveMember2023-01-012023-06-300001463972vuzi:EquityMarketAndOperationalMilestonesEightMember2023-01-012023-06-300001463972vuzi:AnnualRevenueTargetsMember2023-01-012023-06-300001463972vuzi:AnnualEbitdaMarginsBeforeNonCashChargesTargetsMember2023-01-012023-06-300001463972vuzi:AtomisticSasMember2023-01-012023-06-300001463972srt:MinimumMembervuzi:AtomisticAgreementMember2023-01-012023-06-300001463972srt:MaximumMembervuzi:AtomisticAgreementMember2023-01-012023-06-300001463972vuzi:AtomisticAgreementMember2023-06-300001463972us-gaap:TreasuryStockCommonMember2023-01-012023-06-300001463972us-gaap:TreasuryStockCommonMember2022-01-012022-06-3000014639722023-01-012023-03-3100014639722022-03-020001463972us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001463972us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001463972us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001463972us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001463972us-gaap:CommonStockMember2023-04-012023-06-300001463972us-gaap:CommonStockMember2023-01-012023-06-300001463972us-gaap:CommonStockMember2022-04-012022-06-300001463972us-gaap:CommonStockMember2022-01-012022-06-300001463972us-gaap:RetainedEarningsMember2023-06-300001463972us-gaap:AdditionalPaidInCapitalMember2023-06-300001463972us-gaap:RetainedEarningsMember2023-03-310001463972us-gaap:AdditionalPaidInCapitalMember2023-03-3100014639722023-03-310001463972us-gaap:RetainedEarningsMember2022-12-310001463972us-gaap:AdditionalPaidInCapitalMember2022-12-310001463972us-gaap:RetainedEarningsMember2022-06-300001463972us-gaap:AdditionalPaidInCapitalMember2022-06-300001463972us-gaap:RetainedEarningsMember2022-03-310001463972us-gaap:AdditionalPaidInCapitalMember2022-03-3100014639722022-03-310001463972us-gaap:RetainedEarningsMember2021-12-310001463972us-gaap:AdditionalPaidInCapitalMember2021-12-310001463972us-gaap:TreasuryStockCommonMember2023-06-300001463972us-gaap:CommonStockMember2023-06-300001463972us-gaap:TreasuryStockCommonMember2023-03-310001463972us-gaap:CommonStockMember2023-03-310001463972us-gaap:TreasuryStockCommonMember2022-12-310001463972us-gaap:CommonStockMember2022-12-310001463972us-gaap:TreasuryStockCommonMember2022-06-300001463972us-gaap:CommonStockMember2022-06-300001463972us-gaap:TreasuryStockCommonMember2022-03-310001463972us-gaap:CommonStockMember2022-03-310001463972us-gaap:CommonStockMember2021-12-310001463972srt:MinimumMembervuzi:AtomisticAgreementMember2023-06-300001463972srt:MaximumMembervuzi:AtomisticAgreementMember2023-06-3000014639722022-01-012022-12-310001463972us-gaap:EmployeeStockOptionMember2023-06-300001463972us-gaap:EmployeeStockOptionMember2022-12-310001463972vuzi:BoardOfDirectorsAndManagementMember2023-04-012023-06-300001463972us-gaap:EmployeeStockOptionMembervuzi:LongTermIncentivePlan2021Member2021-03-172021-03-170001463972us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001463972us-gaap:EmployeeStockOptionMembervuzi:LongTermIncentivePlan2021Member2021-03-170001463972us-gaap:EmployeeStockOptionMembervuzi:LongTermIncentivePlan2021Member2023-04-012023-06-300001463972us-gaap:EmployeeStockOptionMembervuzi:LongTermIncentivePlan2021Member2023-01-012023-06-300001463972us-gaap:EmployeeStockOptionMembervuzi:LongTermIncentivePlan2021Member2022-04-012022-06-300001463972us-gaap:EmployeeStockOptionMembervuzi:LongTermIncentivePlan2021Member2022-01-012022-06-300001463972vuzi:LicensesMember2023-01-012023-06-300001463972vuzi:SmartGlassesAndIWearVideoHeadphonesSalesMember2023-04-012023-06-300001463972vuzi:EngineeringServicesMember2023-04-012023-06-300001463972vuzi:SmartGlassesAndIWearVideoHeadphonesSalesMember2023-01-012023-06-300001463972vuzi:EngineeringServicesMember2023-01-012023-06-300001463972vuzi:SmartGlassesAndIWearVideoHeadphonesSalesMember2022-04-012022-06-300001463972vuzi:EngineeringServicesMember2022-04-012022-06-300001463972vuzi:SmartGlassesAndIWearVideoHeadphonesSalesMember2022-01-012022-06-300001463972vuzi:EngineeringServicesMember2022-01-012022-06-300001463972us-gaap:SoftwareDevelopmentMember2020-12-310001463972vuzi:ToolingAndManufacturingEquipmentMember2023-06-300001463972vuzi:FurnitureAndEquipmentMember2023-06-300001463972us-gaap:LeaseholdImprovementsMember2023-06-300001463972us-gaap:ComputerSoftwareIntangibleAssetMember2023-06-300001463972vuzi:ToolingAndManufacturingEquipmentMember2022-12-310001463972vuzi:FurnitureAndEquipmentMember2022-12-310001463972us-gaap:LeaseholdImprovementsMember2022-12-310001463972us-gaap:ComputerSoftwareIntangibleAssetMember2022-12-310001463972us-gaap:SeriesAPreferredStockMember2023-06-300001463972us-gaap:SeriesAPreferredStockMember2022-12-310001463972vuzi:ToolingAndManufacturingEquipmentMember2023-01-012023-06-300001463972us-gaap:SoftwareDevelopmentMember2023-01-012023-03-310001463972us-gaap:SoftwareDevelopmentMember2022-01-012022-03-310001463972us-gaap:SoftwareDevelopmentMember2021-10-012023-06-300001463972us-gaap:SoftwareDevelopmentMember2021-10-012021-10-310001463972us-gaap:SoftwareDevelopmentMember2020-01-012020-12-310001463972us-gaap:RetainedEarningsMember2023-04-012023-06-300001463972us-gaap:RetainedEarningsMember2023-01-012023-06-300001463972us-gaap:RetainedEarningsMember2022-04-012022-06-300001463972us-gaap:RetainedEarningsMember2022-01-012022-06-300001463972vuzi:AtomisticSasMember2023-06-300001463972vuzi:AtomisticSasMemberus-gaap:LicensingAgreementsMember2023-06-300001463972us-gaap:SoftwareDevelopmentMember2023-06-300001463972us-gaap:LicensingAgreementsMember2023-06-300001463972us-gaap:SoftwareDevelopmentMember2022-12-310001463972us-gaap:LicensingAgreementsMember2022-12-310001463972srt:MaximumMembervuzi:UkBasedPublicCompanyMember2023-06-300001463972vuzi:PrivateCorporationMember2023-06-300001463972vuzi:PrivateCorporationMember2021-12-310001463972srt:MinimumMembervuzi:StockOptionsTiedToEquityMarketCapitalizationMilestoneMember2023-01-012023-06-300001463972srt:MaximumMembervuzi:StockOptionsTiedToEquityMarketCapitalizationMilestoneMember2023-01-012023-06-300001463972vuzi:StockOptionsTiedToEquityMarketCapitalizationMilestoneMember2023-06-300001463972us-gaap:SoftwareDevelopmentMember2023-01-012023-06-300001463972us-gaap:SoftwareDevelopmentMember2022-01-012022-12-310001463972srt:ScenarioPreviouslyReportedMember2022-04-012022-06-300001463972srt:ScenarioPreviouslyReportedMember2022-01-012022-06-300001463972vuzi:RevisionOfPriorPeriodAsRestatedMember2022-04-012022-06-300001463972srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-04-012022-06-3000014639722022-04-012022-06-300001463972vuzi:RevisionOfPriorPeriodAsRestatedMember2022-01-012022-06-300001463972srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-01-012022-06-300001463972us-gaap:ProductMember2023-04-012023-06-300001463972us-gaap:EnergyServiceMember2023-04-012023-06-300001463972us-gaap:ProductMember2023-01-012023-06-300001463972us-gaap:EnergyServiceMember2023-01-012023-06-300001463972us-gaap:ProductMembervuzi:RevisionOfPriorPeriodAsRestatedMember2022-04-012022-06-300001463972us-gaap:ProductMembersrt:ScenarioPreviouslyReportedMember2022-04-012022-06-300001463972us-gaap:ProductMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-04-012022-06-300001463972us-gaap:EnergyServiceMembervuzi:RevisionOfPriorPeriodAsRestatedMember2022-04-012022-06-300001463972us-gaap:EnergyServiceMembersrt:ScenarioPreviouslyReportedMember2022-04-012022-06-300001463972us-gaap:ProductMember2022-04-012022-06-300001463972us-gaap:EnergyServiceMember2022-04-012022-06-300001463972us-gaap:ProductMembervuzi:RevisionOfPriorPeriodAsRestatedMember2022-01-012022-06-300001463972us-gaap:ProductMembersrt:ScenarioPreviouslyReportedMember2022-01-012022-06-300001463972us-gaap:ProductMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-01-012022-06-300001463972us-gaap:EnergyServiceMembervuzi:RevisionOfPriorPeriodAsRestatedMember2022-01-012022-06-300001463972us-gaap:EnergyServiceMembersrt:ScenarioPreviouslyReportedMember2022-01-012022-06-300001463972us-gaap:ProductMember2022-01-012022-06-300001463972us-gaap:EnergyServiceMember2022-01-012022-06-300001463972vuzi:OneCustomerMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001463972vuzi:TwoCustomersMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001463972vuzi:OneCustomerMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001463972vuzi:TwoCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001463972vuzi:OneCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001463972vuzi:OneCustomerMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001463972vuzi:OneCustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001463972vuzi:OneCustomerMemberus-gaap:ProductMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-3000014639722022-06-3000014639722021-12-3100014639722022-01-012022-06-300001463972vuzi:CapitalizedSoftwareDevelopmentCostsMember2023-04-012023-06-300001463972us-gaap:LicensingAgreementsMember2023-04-012023-06-300001463972vuzi:CapitalizedSoftwareDevelopmentCostsMember2023-01-012023-06-300001463972us-gaap:LicensingAgreementsMember2023-01-012023-06-300001463972vuzi:CapitalizedSoftwareDevelopmentCostsMember2022-04-012022-06-300001463972us-gaap:LicensingAgreementsMember2022-04-012022-06-300001463972vuzi:CapitalizedSoftwareDevelopmentCostsMember2022-01-012022-06-300001463972us-gaap:LicensingAgreementsMember2022-01-012022-06-3000014639722023-06-3000014639722022-12-3100014639722023-04-012023-06-3000014639722023-08-0800014639722023-01-012023-06-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purevuzi:productvuzi:customer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-35955

VUZIX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

    

04-3392453

State or other jurisdiction of
incorporation or organization

(I.R.S. Employer
Identification No.)

25 Hendrix Road, Suite A
West Henrietta, New York

    

14586

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (585359-5900

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

    

Trading Symbol(s)

    

Name of each exchange on which registered:

Common Stock, par value $0.001

 

VUZI

 

Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days.   Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

 

 

 

 

 

 

Smaller reporting company

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes No 

As of August 8, 2023, there were 63,319,217 shares of the registrant’s common stock outstanding.

Vuzix Corporation

INDEX

 

Page
No.

 

 

Part I – Financial Information

3

 

 

Item 1.

Consolidated Financial Statements (Unaudited):

3

 

Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022

3

 

Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 2023 and 2022

4

 

Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2023 and 2022

5

 

Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022

6

 

Notes to the Unaudited Consolidated Financial Statements

7

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

25

 

Item 4.

Controls and Procedures

25

 

Part II – Other Information

26

 

Item 1.

Legal Proceedings

26

 

Item 1A.

Risk Factors

26

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

26

 

Item 3.

Defaults Upon Senior Securities

26

 

Item 4.

Mine Safety Disclosure

26

 

Item 5.

Other Information

26

 

Item 6.

Exhibits

27

 

 

Signatures

28

2

Part 1: FINANCIAL INFORMATION

Item 1: Consolidated Financial Statements

VUZIX CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited)

    

June 30, 

December 31, 

    

2023

    

2022

ASSETS

 

  

 

  

Current Assets

 

  

 

  

Cash and Cash Equivalents

$

48,582,005

$

72,563,943

Accounts Receivable, Net

 

6,545,608

 

3,558,971

Accrued Revenues in Excess of Billings

 

309,762

 

269,129

Employee Retention Credit Receivable

466,705

Inventories, Net

 

10,870,166

 

11,267,969

Manufacturing Vendor Prepayments

 

353,399

 

998,671

Prepaid Expenses and Other Assets

 

1,660,374

 

2,115,853

Total Current Assets

 

68,321,314

 

91,241,241

Long-Term Assets

 

  

 

  

Fixed Assets, Net

 

6,814,005

 

3,878,505

Operating Lease Right-of-Use Asset

628,131

956,165

Patents and Trademarks, Net

 

2,438,299

 

2,220,094

Technology Licenses, Net

 

28,504,870

 

30,158,689

Intangible Asset, Net

 

605,453

 

675,313

Goodwill

 

1,601,400

 

1,601,400

Other Assets, Net

 

1,649,132

 

1,581,143

Total Assets

$

110,562,604

$

132,312,550

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

  

Current Liabilities

 

  

 

  

Accounts Payable

$

1,620,490

$

1,211,747

Unearned Revenue

 

107,043

 

29,064

Accrued Expenses

 

1,029,177

 

1,670,539

Licensing Fees Commitment

 

3,500,000

 

11,500,000

Income and Other Taxes Payable

 

138,959

 

214,997

Operating Lease Right-of-Use Liability

429,421

651,011

Total Current Liabilities

 

6,825,090

 

15,277,358

Long-Term Liabilities

Operating Lease Right-of-Use Liability

198,710

305,154

Total Liabilities

 

7,023,800

 

15,582,512

Stockholders' Equity

 

  

 

  

Common Stock - $0.001 Par Value, 100,000,000 shares authorized; 63,898,889 shares issued and 63,319,217 shares outstanding as of June 30, 2023 and 63,783,779 shares issued and 63,319,107 shares outstanding as of December 31, 2022.

 

63,899

 

63,783

Additional Paid-in Capital

 

369,072,625

 

362,507,715

Accumulated Deficit

 

(263,121,219)

 

(243,835,716)

Treasury Stock, at cost, 579,672 shares as of June 30, 2023 and 464,672 shares as of December 31, 2022.

 

(2,476,501)

 

(2,005,744)

Total Stockholders' Equity

 

103,538,804

 

116,730,038

Total Liabilities and Stockholders' Equity

$

110,562,604

$

132,312,550

The accompanying notes are an integral part of these consolidated financial statements.

3

VUZIX CORPORATION

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

Common Stock

Additional

Accumulated

Treasury Stock

    

Shares

    

Amount

    

Paid-In Capital

    

Deficit

    

Shares

    

Amount

    

Total

Balance - April 1, 2023

 

63,787,858

$

63,787

$

365,868,487

$

(254,076,299)

(579,672)

$

(2,476,501)

$

109,379,474

Stock-Based Compensation Expense

 

96,525

 

97

 

3,189,606

 

 

 

 

3,189,703

Stock Option Exercises

 

14,506

 

15

 

14,532

 

 

 

 

14,547

Net Loss

 

 

 

 

(9,044,920)

 

 

 

(9,044,920)

Balance - June 30, 2023

 

63,898,889

$

63,899

$

369,072,625

$

(263,121,219)

 

(579,672)

$

(2,476,501)

$

103,538,804

Common Stock

Additional

Accumulated

Treasury Stock

    

Shares

    

Amount

    

Paid-In Capital

    

Deficit

    

Shares

    

Amount

    

Total

Balance - January 1, 2023

 

63,783,779

$

63,783

$

362,507,715

$

(243,835,716)

(464,672)

$

(2,005,744)

$

116,730,038

Stock-Based Compensation Expense

 

96,525

 

97

 

6,550,382

 

 

 

 

6,550,479

Stock Option Exercises

 

18,585

 

19

 

14,528

 

 

 

 

14,547

Purchases of Treasury Stock

 

 

 

 

 

(115,000)

 

(470,757)

 

(470,757)

Net Loss

 

 

 

 

(19,285,503)

 

 

 

(19,285,503)

Balance - June 30, 2023

 

63,898,889

$

63,899

$

369,072,625

$

(263,121,219)

 

(579,672)

$

(2,476,501)

$

103,538,804

Common Stock

Additional

Accumulated

Treasury Stock

    

Shares

    

Amount

    

Paid-In Capital

    

Deficit

    

Shares

    

Amount

    

Total

Balance - April 1, 2022

 

63,704,626

$

63,705

$

350,721,326

$

(213,578,143)

(36,685)

$

(251,057)

$

136,955,831

Stock-Based Compensation Expense

 

288,650

 

289

 

4,582,414

 

 

 

 

4,582,703

Stock Option Exercises

 

32,364

 

32

 

19,250

 

 

 

 

19,282

Net Loss

 

 

 

 

(10,021,668)

 

 

 

(10,021,668)

Balance - June 30, 2022

 

64,025,640

$

64,026

$

355,322,990

$

(223,599,811)

 

(36,685)

$

(251,057)

$

131,536,148

Common Stock

Additional

Accumulated

Treasury Stock

    

Shares

    

Amount

    

Paid-In Capital

    

Deficit

    

Shares

    

Amount

    

Total

Balance - January 1, 2022

 

63,672,268

$

63,672

$

346,736,397

$

(203,072,143)

$

$

143,727,926

Stock-Based Compensation Expense

 

288,650

 

289

 

8,538,153

 

 

 

 

8,538,442

Stock Option Exercises

 

64,722

 

65

 

48,440

 

 

 

 

48,505

Purchases of Treasury Stock

 

 

 

 

 

(36,685)

 

(251,057)

 

(251,057)

Net Loss

 

 

 

 

(20,527,668)

 

 

 

(20,527,668)

Balance - June 30, 2022

 

64,025,640

$

64,026

$

355,322,990

$

(223,599,811)

 

(36,685)

$

(251,057)

$

131,536,148

The accompanying notes are an integral part of these consolidated financial statements.

4

VUZIX CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2023

    

2022

    

2023

    

2022

Sales:

 

  

 

  

 

  

 

  

Sales of Products

$

4,425,162

$

2,898,892

$

8,616,523

$

5,401,944

Sales of Engineering Services

 

265,673

 

108,866

 

265,673

 

108,866

Total Sales

 

4,690,835

 

3,007,758

 

8,882,196

 

5,510,810

Cost of Sales:

 

  

 

  

 

  

 

  

Cost of Sales - Products Sold

 

3,303,979

 

2,451,890

 

6,386,418

 

4,255,488

Cost of Sales - Depreciation and Amortization

257,939

231,163

490,855

454,949

Cost of Sales - Engineering Services

 

156,531

 

59,296

 

156,531

 

59,296

Total Cost of Sales

 

3,718,449

 

2,742,349

 

7,033,804

 

4,769,733

Gross Profit

 

972,386

 

265,409

 

1,848,392

 

741,077

Operating Expenses:

 

  

 

  

 

  

 

  

Research and Development

 

2,836,552

 

2,996,144

 

5,906,349

 

6,099,588

Selling and Marketing

 

2,509,922

 

1,850,595

 

5,049,581

 

3,914,584

General and Administrative

 

4,260,322

 

5,039,949

 

9,392,146

 

10,453,228

Depreciation and Amortization

 

973,222

 

379,702

 

1,937,487

 

638,946

Impairment of Patents and Trademarks

 

 

 

17,666

 

49,602

Total Operating Expenses

 

10,580,018

 

10,266,390

 

22,303,229

 

21,155,948

Loss From Operations

 

(9,607,632)

 

(10,000,981)

 

(20,454,837)

 

(20,414,871)

Other Income (Expense):

 

  

 

  

 

  

 

  

Investment Income

 

628,923

 

111,027

 

1,324,706

 

117,307

Income and Other Taxes

 

(35,420)

 

(31,326)

 

(123,215)

 

(78,959)

Foreign Exchange Loss

 

(30,791)

 

(100,388)

 

(32,157)

 

(151,145)

Total Other Income (Expense), Net

 

562,712

 

(20,687)

 

1,169,334

 

(112,797)

Loss Before Provision for Income Taxes

 

(9,044,920)

 

(10,021,668)

 

(19,285,503)

 

(20,527,668)

Provision for Income Taxes

 

 

 

 

Net Loss

 

(9,044,920)

 

(10,021,668)

 

(19,285,503)

 

(20,527,668)

Basic and Diluted Loss per Common Share

$

(0.14)

$

(0.16)

$

(0.31)

$

(0.32)

Weighted-average Shares Outstanding - Basic and Diluted

 

63,230,859

 

63,739,863

 

63,223,768

 

63,717,618

The accompanying notes are an integral part of these consolidated financial statements.

5

VUZIX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Six Months Ended June 30, 

    

2023

    

2022

Cash Flows from Operating Activities

 

  

 

  

Net Loss

$

(19,285,503)

$

(20,527,668)

Non-Cash Adjustments

 

  

 

  

Depreciation and Amortization

 

2,428,342

 

1,093,895

Stock-Based Compensation

 

6,500,261

 

8,200,774

Impairment of Patents and Trademarks

 

17,666

 

49,602

Change in Inventory Reserve for Obsolescence

480,258

(Increase) Decrease in Operating Assets

 

  

 

  

Accounts Receivable

 

(2,986,637)

 

678,523

Accrued Revenues in Excess of Billings

 

(40,633)

 

(108,866)

Employee Retention Credit Receivable

466,705

Inventories

 

(82,454)

 

359,893

Manufacturing Vendor Prepayments

 

645,272

 

(654,569)

Prepaid Expenses and Other Assets

 

1,692

 

492,599

Increase (Decrease) in Operating Liabilities

 

  

 

  

Accounts Payable

 

408,743

 

(732,813)

Accrued Expenses

 

(641,362)

 

195,276

Unearned Revenue

 

77,980

 

12,829

Income and Other Taxes Payable

 

(76,037)

 

(76,384)

Net Cash Flows Used in Operating Activities

 

(12,085,707)

 

(11,016,909)

Cash Flows from Investing Activities

 

  

 

  

Purchases of Fixed Assets

 

(2,774,513)

 

(3,504,931)

Investments in Patents and Trademarks

 

(340,507)

 

(272,686)

Investments in Licenses, Intangibles and Other Assets

 

(8,000,000)

 

(4,625,000)

Investments in Software Development

(125,000)

Investments in Other Assets

 

(200,000)

 

Net Cash Flows Used in Investing Activities

 

(11,440,020)

 

(8,402,617)

Cash Flows from (used) Financing Activities

 

  

 

  

Proceeds from Exercise of Stock Options

 

14,546

 

48,505

Purchases of Treasury Stock

(470,757)

(251,057)

Net Cash Flows Used in Financing Activities

 

(456,211)

 

(202,552)

Net Decrease in Cash and Cash Equivalents

 

(23,981,938)

 

(19,622,078)

Cash and Cash Equivalents - Beginning of Period

 

72,563,943

 

120,203,873

Cash and Cash Equivalents - End of Period

$

48,582,005

$

100,581,795

Supplemental Disclosures

 

  

 

  

Unamortized Common Stock Expense included in Prepaid Expenses and Other Assets

$

1,335,307

$

1,223,691

Non-Cash Investment in Licenses

3,500,000

10,500,000

Stock-Based Compensation Expense - Expensed less Previously Issued

(50,218)

(337,379)

The accompanying notes are an integral part of these consolidated financial statements.

6

VUZIX CORPORATION

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Note 1 – Basis of Presentation

The accompanying unaudited consolidated financial statements of Vuzix Corporation (“the Company” or “Vuzix”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, the unaudited consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Certain re-classifications have been made to prior comparable periods to conform with current reporting impacting Costs of Sales, Gross Profit and Depreciation and Amortization. The results of the Company’s operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results of the Company’s operations for the full fiscal year or any other period.

The accompanying interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto of the Company as of and for the year ended December 31, 2022, as reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2023.

Re-classification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year’s presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Operations for the three and six months ended June 30, 2022, to reclassify depreciation expense related to our manufacturing operations from the amounts of reported depreciation and amortization expenses originally included in Operating Expenses. This change in classification does not affect previously reported Net Loss or reported Cash Flows Used in Operating Activities in the Consolidated Statements of Cash Flows or Consolidated Balance Sheets. The below table is a summary of the impact of these re-classifications:

For the Three Months Ended June 30, 2022

For the Six Months Ended June, 2022

As Previously

As Previously

Condensed Statement of Operations

    

Presented

    

Re-classification

    

Revised

    

Presented

    

Re-classification

    

Revised

Total Sales

$

3,007,758

$

$

3,007,758

$

5,510,810

$

$

5,510,810

Cost of Sales - Products Sold

2,522,674

(70,784)

2,451,890

4,386,371

(130,883)

4,255,488

Cost of Sales - Depreciation and Amortization

231,163

231,163

454,949

454,949

Cost of Sales - Engineering Services

59,296

59,296

59,296

59,296

Gross Profit

425,788

160,379

265,409

1,065,143

324,066

741,077

Operating Expenses:

Research and Development

2,996,144

2,996,144

6,099,588

6,099,588

Selling and Marketing

1,850,595

1,850,595

3,914,584

3,914,584

General and Administrative

5,039,949

5,039,949

10,453,228

10,453,228

Depreciation and Amortization

540,081

(160,379)

379,702

963,012

(324,066)

638,946

Impairment of Patents and Trademarks

49,602

49,602

Total Operating Expenses

10,426,769

(160,379)

10,266,390

21,480,014

(324,066)

21,155,948

Loss From Operations

 

(10,000,981)

 

 

(10,000,981)

 

(20,414,871)

 

 

(20,414,871)

Total Other Expense, Net

(20,687)

(20,687)

(112,797)

(112,797)

Net Loss

$

(10,021,668)

$

$

(10,021,668)

$

(20,527,668)

$

$

(20,527,668)

Customer Concentrations

For the three months ended June 30, 2023, one customer represented 75% of total product revenue. For the three months ended June 30, 2022, one customer represented 45% of total product revenue.

7

For the six months ended June 30, 2023, two customers represented 40% and 35% of total product revenue. For the six months ended June 30, 2022, one customer represented 24% of total product revenue.

As of June 30, 2023, two customers represented 58% and 23% of accounts receivable. As of December 31, 2022, one customer represented 26% of accounts receivable.

Treasury Stock

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains and losses on the subsequent re-issuance of shares will be credited or charged to paid-in capital in excess of par value using the average-cost method.

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). ASU 2016-13 provides for a new impairment model which requires measurement and recognition of expected credit losses for most financial assets and certain other instruments, including but not limited to, accounts receivable. The Company adopted ASU 2016-13 effective on January 1, 2023. The adoption of this standard did not have a material impact on our consolidated financial statements.

Note 2 – Revenue Recognition and Contracts with Customers

Disaggregated Revenue

The Company’s total revenue was comprised of two major product lines: Smart Glasses Sales and Engineering Services. The following table summarizes the revenue recognized by major product line:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2023

    

2022

    

2023

    

2022

Revenues

 

  

 

  

 

  

 

  

Products Sales

$

4,425,162

$

2,898,892

$

8,616,523

$

5,401,944

Engineering Services

 

265,673

 

108,866

 

265,673

 

108,866

Total Revenue

$

4,690,835

$

3,007,758

$

8,882,196

$

5,510,810

Significant Judgments

Under Topic 606 “Revenue from Contracts with Customers”, we use judgments that could potentially impact both the timing of our satisfaction of performance obligations and our determination of transaction prices used in determining revenue recognized by major product line. Such judgments include considerations in determining our transaction prices and when our performance obligations are satisfied for our standard product sales that include an end-user 30-day right to return if not satisfied with product and general payment terms that are between Net 30 and 60 days. For our engineering services, performance obligations are recognized over time using the input method and the estimated costs to complete each project are considered significant judgments.

Performance Obligations

Revenues from our performance obligations are typically satisfied at a point-in-time for Smart Glasses, Waveguides and Display Engines, and our OEM Products, which are recognized when the customer obtains control and ownership, which is generally upon shipment. The Company considers shipping and handling activities performed to be fulfillment activities and not a separate performance obligation. The Company also records revenue for performance obligations relating to our engineering services over time by using the input method measuring progress toward satisfying the performance obligations. Satisfaction of our performance obligations related to our engineering services is

8

measured by the Company’s costs incurred as a percentage of total expected costs to project completion as the inputs of actual costs incurred by the Company are directly correlated with progress toward completing the contract. As such, the Company believes that our methodologies for recognizing revenue over time for our engineering services correlate directly with the transfer of control of the underlying assets to our customers.

Our standard product sales include a twelve (12) month assurance-type product warranty. In the case of certain of our OEM products and waveguide sales, some include a standard product warranty of up to eighteen (18) months to allow distribution channels to offer the end customer a full twelve (12) months of coverage. We offer extended warranties to customers, which extend the standard product warranty on product sales for an additional twelve (12) month period. All revenue related to extended product warranty sales is deferred and recognized over the extended warranty period. Our engineering services contracts vary from contract to contract but typically include payment terms of Net 30 days from the date of billing, subject to an agreed upon customer acceptance period.

The following table presents a summary of the Company’s sales by revenue recognition method as a percentage of total net sales for the six months ended June 30:

    

% of Total Net Sales

2023

 

2022

 

Point-in-Time

 

97%

%

98%

%

Over Time – Input Method

 

3%

%

2%

%

Total

 

100%

%

100%

%

Remaining Performance Obligations

As of June 30, 2023, the Company had approximately $80,000 of remaining performance obligations under a current waveguide development project, which represents the remainder of the total transaction price of approximately $800,000 under this development agreement, which commenced in 2022, less revenue recognized under percentage of completion to date. The Company expects to recognize the remaining revenue related to this project in the third quarter of 2023. Revenues earned less amounts invoiced at June 30, 2023 in the amount of $309,762 are reflected as Accrued Revenues in Excess of Billings in the accompanying Consolidated Balance Sheet.

The Company had no material outstanding performance obligations related to product sales, other than its standard product warranty.

Note 3 – Loss Per Share

Basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution from the assumed exercise of stock options. During periods of net loss, all common stock equivalents are excluded from the diluted EPS calculation because they are anti-dilutive. Since the Company reported a net loss for the three and six months ended June 30, 2023 and 2022, the calculation for basic and diluted earnings per share is considered to be the same, as the impact of potential common shares is anti-dilutive. As of June 30, 2023 and 2022, there were 8,658,642 and 8,528,668 common stock share equivalents, respectively, potentially exercisable or issuable under conversion or exercise of stock options that could dilute basic earnings per share in the future.

9

Note 4 – Inventories, Net

Inventories are stated at the lower of cost and net realizable value, and consisted of the following:

June 30, 

December 31, 

    

2023

    

2022

Purchased Parts and Components

$

9,780,977

$

10,399,527

Work-in-Process

 

518,460

 

344,242

Finished Goods

 

2,468,476

 

1,941,689

Less: Reserve for Obsolescence

 

(1,897,747)

 

(1,417,489)

Inventories, Net

$

10,870,166

$

11,267,969

Note 5 – Fixed Assets

Fixed Assets consisted of the following:

June 30, 

December 31, 

    

2023

    

2022

Tooling and Manufacturing Equipment

$

8,866,022

$

6,065,445

Leaseholds

 

1,472,898

 

826,329

Computers and Purchased Software

 

789,036

 

760,256

Furniture and Equipment

 

2,513,575

 

2,487,650

 

13,641,531

 

10,139,680

Less: Accumulated Depreciation

 

(6,827,526)

 

(6,261,175)

Fixed Assets, Net

$

6,814,005

$

3,878,505

During the six months ended June 30, 2023, the Company invested $2,774,513 in tooling and manufacturing equipment and leasehold improvements, mostly attributable to the Company’s new waveguide expansion project. Construction on the Company’s new facility began late in December 2022 and the Company expects the construction to be completed by the end of September 2023.

Total depreciation expense for fixed assets, not included in cost of sales, for the three months ended June 30, 2023, and 2022 was $111,934 and $111,943, respectively. Total depreciation expense for fixed assets, not included in cost of sales, for the six months ended June 30, 2023, and 2022 was $214,385 and $229,029, respectively.

Note 6 – Technology Licenses, Net

June 30, 

December 31, 

    

2023

    

2022

Licenses

$

32,443,356

$

2,443,356

Additions

 

 

30,000,000

Less: Accumulated Amortization

 

(3,938,486)

 

(2,284,667)

Licenses, Net

$

28,504,870

$

30,158,689

Total amortization expense related to technology licenses for the three months ended June 30, 2023 and 2022 was $826,984 and $244,201, respectively. Total amortization expense related to technology licenses for the six months ended June 30, 2023, and 2022 was $1,653,868 and $300,901, respectively.

The Company signed a series of agreements with Atomistic SAS in 2022, which provided for an exclusive license of key micro LED technology for cash commitments totaling $30 million along with performance-based cash and

10

equity issuance commitments to be made by the Company relating to the certain deliverables and the achievement of milestones by Atomistic, as further discussed in Note 10 – Capital Stock.

These intangible technology license assets are to be amortized over a ten-year period. As of June 30, 2023, there is a remaining funding commitment of $3,500,000 associated with these licenses, that will be paid over the next six months.

Note 7 - Other Assets

June 30,

December 31, 

    

2023

    

2022

Private Corporation Investments

$

450,000

$

450,000

Additions

200,000

Total Private Corporation Investments (at cost)

650,000

450,000

Software Development Costs

875,000

750,000

Additions

125,000

125,000

Less: Accumulated Amortization

(513,889)

(375,000)

Software Development Costs, Net

486,111

500,000

Unamortized Common Stock Expense included in Long-Term Prepaid Expenses

513,021

631,143

Total Other Assets

$

1,649,132

$

1,581,143

In 2021, the Company acquired, for a purchase price of $200,000, an ownership interest of 3%, in the form of preferred stock, in a private corporation developing smart glasses software for use by retailers in the stock keeping of inventory, amongst other uses. In the six months ended June 30, 2023, the Company purchased an additional $100,000 of preferred stock in this corporation through a subsequent round of funding in order to retain a 2% ownership interest.

In June 2023, the Company purchased $100,000 of preferred stock, along with warrants, in a UK-based public company developing new semiconductor materials for displays. The investment represents less than a 1% ownership interest.

During 2020, the Company invested $500,000 in Android operating systems upgrades for its CPU platform used in its M400 and M4000 products. This upgrade was finished and placed into service in the beginning of the fourth quarter of 2020.  This capitalized asset is being amortized on a straight-line basis over its expected product life cycle of thirty-six (36) months, which began on October 1, 2020. In October 2021, the Company invested $250,000 and in the first quarter of 2022 the Company invested an additional $125,000 for further Android operating systems version upgrades to the CPU platform it uses in its M400 and M4000 products. In the six months ended June 30, 2023, the Company made a final investment of $125,000 to these system upgrades, which were placed into service during the quarter. These additional upgrades of $500,000 are being amortized on a straight-line base over thirty-six (36) months.

Total amortization expense related to all software updates for the three months ended June 30, 2023, and 2022 were $83,333 and $41,667, respectively. Total amortization expense related to all software updates for the six months ended June 30, 2023, and 2022 were $138,889 and $83,333, respectively.

11

Note 8 – Accrued Expenses

Accrued expenses consisted of the following:

June 30, 

December 31, 

    

2023

    

2022

Accrued Wages and Related Costs

$

478,116

$

843,537

Accrued Professional Services

 

152,400

 

263,800

Accrued Warranty Obligations

 

198,700

 

159,927

Other Accrued Expenses

 

199,961

 

403,275

Total

$

1,029,177

$

1,670,539

The Company has warranty obligations in connection with the sale of certain of its products. The warranty period for its products is generally twelve (12) months. The costs incurred to provide for these warranty obligations are estimated and recorded as an accrued expense at the time of sale. The Company estimates its future warranty costs based upon product-based historical performance rates and related costs to repair.

The changes in the Company’s accrued warranty obligations for the six months ended June 30, 2023, were as follows:

Accrued Warranty Obligations at December 31, 2022

$

159,927

Reductions for Settling Warranties

 

(219,723)

Warranties Issued During Year

 

258,496

Accrued Warranty Obligations at June 30, 2023

$

198,700

Note 9 – Income Taxes

The Company’s effective income tax rate is a combination of federal, state and foreign tax rates and differs from the U.S. statutory rate due to taxes on foreign income, permanent differences including tax-exempt interest, and the resolution of tax uncertainties, offset by a valuation allowance against U.S. deferred income tax assets.

Note 10 – Capital Stock

Preferred stock

The Board of Directors is authorized to establish and designate different series of preferred stock and to fix and determine their voting powers and other rights and terms. A total of 5,000,000 shares of preferred stock with a par value of $0.001 are authorized as of June 30, 2023, and December 31, 2022. Of this total, 49,626 shares are designated as Series A Preferred Stock. There were nil shares of Series A Preferred Stock issued and outstanding on June 30, 2023, and December 31, 2022, respectively.

Common Stock

The Company’s authorized common stock consists of 100,000,000 shares, par value of $0.001. There were 63,898,889 shares issued and 63,319,217 shares outstanding as of June 30, 2023, and 63,783,779 shares issued and 63,319,107 shares outstanding as of December 31, 2022.

In connection with the Atomistic Technology Licenses discussed in Note 6, the Company will, upon certain deliverables and the achievement of milestones contained in the Atomistic Agreements, be committed to pay $2,500,000 and to issue, depending on the Company’s share price within a $13.00 to $8.00 range at the time of their issuance, a minimum of 1,750,000 up to a maximum of 2,874,754 common shares of Vuzix to the stockholders of Atomistic (as a

12

portion of the consideration for certain shares of Atomistic) which would result in Vuzix owning Series A Preferred shares in Atomistic that could ultimately be converted into ordinary shares of Atomistic and Vuzix ultimately owning 100% of Atomistic. The share issuances by the Company are expected to be issued over the next 6 to 18 months.

Treasury Stock

On March 2, 2022, our Board of Directors approved the Company to repurchase up to an aggregate of $25 million of our common stock by open market or privately negotiated transactions under the Share Buyback Program.  This program was in effect for one year and expired on March 2, 2023. During the three months ended March 31, 2023, the Company repurchased 115,000 shares of our common stock at an average cost of $4.06, before commission of $0.03 per share. As of June 30, 2023, 579,672 shares of our common stock were held in treasury.

Note 11 – Stock-Based Compensation

A summary of stock option activity related to the Company’s standard employee incentive plan (excluding options awarded under the Long-Term Incentive Plan (LTIP) – Note 12) for the six months ended June 30, 2023, is as follows:

Weighted

Average

Number of

Average

Remaining Life

    

Options

    

Exercise Price

    

(years)

Outstanding at December 31, 2022

 

2,805,673

$

7.80

 

7.28

Granted

 

124,000

 

4.80

 

  

Exercised

 

(18,240)

 

1.33

 

  

Expired or Forfeited

 

(36,791)

 

10.64

 

  

Outstanding at June 30, 2023

 

2,874,642

$

7.67

 

6.94

The weighted average remaining contractual term for all options as of June 30, 2023, and December 31, 2022, was 6.94 years and 7.28 years, respectively.

As of June 30, 2023, there were 1,765,244 options that were fully vested and exercisable at a weighted average exercise price of $7.04 per share. The weighted average remaining contractual term of the vested options is 6.1 years.

As of June 30, 2023, there were 1,109,398 unvested options exercisable at a weighted average exercise price of $8.84 per share. The weighted average remaining contractual term of the unvested options is 8.3 years.

The weighted average fair value of option grants was calculated using the Black-Scholes-Merton option pricing method. As of June 30, 2023, the Company had $6,863,003 of unrecognized stock compensation expense, which will be recognized over a weighted average period of 2.2 years.

During the three months ended June 30, 2023, the Company issued 96,525 shares of common stock to its independent board members as part of their annual retainer for services covering the period of July 2023 to June 2024. The fair market value on the date of award of the stock issued was $5.18, resulting in an aggregate fair value of approximately $500,000. The fair market value of these awards is expensed over twelve (12) months, beginning on July 1, 2023.

For the three months ended June 30, 2023, and 2022, the Company recorded total stock-based compensation expense, including stock awards but excluding stock option awards under the Company’s LTIP, of $1,083,064 and $1,222,733, respectively. For the six months ended June 30, 2023, and 2022, the Company recorded total stock-based compensation expense, including stock awards but excluding stock option awards under the Company’s LTIP, of $2,212,630 and $2,573,343, respectively.

13

Note 12 – Long-Term Incentive Plan

On March 17, 2021, the Company granted options to purchase a total of 5,784,000 shares of common stock to its officers and certain other members of its management team. The options were granted under the Company’s existing 2014 Incentive Stock Plan. The options have an exercise price of $19.00, with 375,000 options vesting immediately and the remaining portion vesting upon the achievement of certain equity market capitalization milestones, and revenue and EBITDA operational milestones. For the three months ended June 30, 2023, and 2022, the Company recorded non-cash stock-based compensation expense of $1,749,687 and $2,658,294, respectively, for options that vested or are probable to vest. For the six months ended June 30, 2023, and 2022, the Company recorded non-cash stock-based compensation expense of $4,287,631 and $5,627,432, respectively, for options that vested or are probable to vest. These expenses are presented in the same financial statement line items in the Statements of Operations as the cash-based compensation expenses for the same employees.

The fair value of option grants was calculated using a Monte Carlo simulation for the equity market capitalization tranches and the Black-Scholes-Merton option pricing method for the operational milestone tranches. As of June 30, 2023, we had $12,922,301 of total unrecognized stock-based compensation expense for the portion of options tied to equity market capitalization milestones and the portion of options tied to operational milestones that were considered probable of achievement, all of which will be recognized over a service period of up to three to four years. The probabilities of the milestone achievements are subject to catch-up adjustments in each instance where an equity market capitalization milestone is achieved or when an operational milestone becomes probable to be achieved or is achieved. Compensation costs could be reversed in subsequent periods if an awardee leaves the Company prior to the expiration of the option life for market capitalization milestone or performance award vesting of a performance award no longer determined to be probable. If such milestones are achieved earlier in their expected service periods, the remaining unrecognized compensation expense related to that particular milestone would be accelerated and recognized in full during the period where that achievement is affirmed by the Board of Directors. As of June 30, 2023, and going forward, should all of the operational milestones which are currently not yet deemed probable of achievement become probable of achievement or are achieved, then the Company could ultimately recognize up to an additional $34.1 million in non-cash stock-based compensation expense at such time.

The unvested remaining equity market and operational milestones under the LTIP with their total related option grants and criteria achievement weightings of the options available for meeting a target are shown in the following table. Of the total 5,409,000 unvested options outstanding as of June 30, 2023, there are 2,704,500 options unvested for the achievement of Equity Market Capitalization targets, 1,893,150 unvested options for the achievement of annual Revenue targets, and 811,350 unvested options for the achievement of annual EBITDA Margins Before Non-Cash Charges targets.

Award Potential

Criteria Achievement Weighting

50% of Options Available

35% of Options Available

15% of Options Available

Options Available
(Subject to Vesting)

Equity Market
Capitalization
Target

Last Twelve Months Revenue
Target

Last Twelve Months EBITDA Target

686,000

$ 2,000,000,000

$ 25,000,000

0.0%

686,000

3,000,000,000

50,000,000

2.0%

686,000

4,000,000,000

100,000,000

4.0%

686,000

5,000,000,000

200,000,000

6.0%

586,000

6,000,000,000

300,000,000

8.0%

586,000

7,000,000,000

450,000,000

10.0%

561,000

8,000,000,000

675,000,000

12.0%

491,000

9,000,000,000

1,000,000,000

14.0%

441,000

10,000,000,000

1,500,000,000

16.0%

5,409,000

Note 13 – Litigation

We are not currently involved in any actual or pending legal proceedings or litigation that we consider to be material, and we are not aware of any such material proceedings contemplated by or against us or involving our property.

14

Note 14 – Right-of-Use Assets and Liabilities

Future lease payments under operating leases as of June 30, 2023 were as follows:

2023 (6 months remaining)

$

348,826

2024

 

191,120

2025

 

132,982

Total Future Lease Payments

 

672,928

Less: Imputed Interest

 

(44,797)

Total Lease Liability Balance

$

628,131

Operating lease costs under the operating leases totaled $207,352 and $163,277 for the three months ended June 30, 2023, and 2022, respectively. Operating lease costs under the operating leases totaled $410,691 and $325,642 for the six months ended June 30, 2023, and 2022, respectively.

As of June 30, 2023, the weighted average discount rate was 7.1% and the weighted average remaining lease term was 1.5 years.

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of financial condition and results of operations in conjunction with the financial statements and related notes appearing elsewhere in this quarterly report and in our Annual Report on Form 10-K for the year ended December 31, 2022.

As used in this report, unless otherwise indicated, the terms “Company,” “Vuzix”, “management,” “we,” “our,” and “us” refer to Vuzix Corporation.

Critical Accounting Policies and Significant Developments and Estimates

The discussion and analysis of our financial condition and results of operations is based upon our unaudited consolidated financial statements and related notes appearing elsewhere in this quarterly report. The preparation of these statements in conformity with GAAP requires the appropriate application of certain accounting policies, many of which require us to make estimates and assumptions about future events and their impact on amounts reported in our consolidated financial statements, including the statement of operations, balance sheet, cash flow and related notes. We continually evaluate our estimates used in the preparation of our financial statements, including those related to revenue recognition, bad debts, inventories, warranty reserves, product warranty, carrying value of long-lived assets, fair value measurement of financial instruments, valuation of stock compensation awards, achievement of equity market capitalization and probability of operational milestones being achieved under our LTIP, and income taxes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not apparent from other sources. Since future events and their impact cannot be determined with certainty, the actual results will inevitably differ from our estimates. Such differences could be material to the consolidated financial statements.

We believe that our application of accounting policies, and the estimates inherently required therein, are reasonable. We periodically re-evaluate these accounting policies and estimates and make adjustments when facts and circumstances dictate. Historically, we have found our application of accounting policies to be appropriate, and actual results have not differed materially from those determined using such necessary estimates.

15

Management believes certain factors and trends are important in understanding our financial performance. The critical accounting policies, judgments and estimates that we believe have the most significant effect on our consolidated financial statements are:

Valuation of inventories;
Variable Interest Entities;
Business combinations;
Carrying value of long-lived assets;
Software development costs;
Revenue recognition;
Product warranty;
Stock-based compensation; and
Income taxes.

Our accounting policies are more fully described in the notes to our consolidated financial statements included in this quarterly report and in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no significant changes in our accounting policies for the three months ended June 30, 2023.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, an effect on our financial condition, financial statements, revenues or expenses.

Business Matters

We are engaged in the design, manufacture, marketing and sale of wearable computing devices and augmented reality wearable display devices, also referred to as head mounted displays (or HMDs), heads-up displays (HUDs) or near-eye displays, in the form of Smart Glasses and Augmented Reality (AR) glasses. Our wearable display devices are worn like eyeglasses or attach to a head-worn mount. These devices typically include cameras, sensors, and a computer that enable the user to view, record and interact with video and digital content, such as computer data, the internet, social media or entertainment applications. Our wearable display products integrate display technology with our advanced optics to produce compact high-resolution display engines, less than half an inch diagonally, which when viewed through our Smart Glasses products create virtual images that appear comparable in size to that of a computer monitor or a large-screen television.

With respect to our Smart Glasses and AR products, we are focused on the enterprise, industrial, commercial, security, first responder, medical, and defense markets. We also provide custom solutions and engineering services to third parties, including OEMs, of waveguides to enable fully-integrated wearable display systems, including HMDs to commercial, industrial and defense customers. We do not offer “work-for-hire” services per se but rather offer our engineering services for projects that we expect could result in advancing our technology and potentially lead to long-term supply or OEM relationships.

All of the mobile displays and wearable and mobile electronics markets in which we compete, including mobile and wearable displays and electronics, have been and continue to be subject to consistent and rapid technological change, with ever greater capabilities and performance, including mobile devices with larger screen sizes and improved display resolutions as well as, in many cases, reductions in pricing for mobile devices. As a result, we must continue to

16

improve our products’ performance and lower our costs. We believe our intellectual property portfolio gives us a leadership position in the design and manufacturing of micro-display projection engines, waveguides, mechanical packaging, ergonomics, and optical systems.

Recent Accounting Pronouncements

See Note 1 to the Unaudited Consolidated Financial Statements.

Results of Operations

Comparison of Three Months Ended June 30, 2023 and 2022

The following table compares the Company’s consolidated statements of operations data for the three months ended June 30, 2023 and 2022:

Three Months Ended June 30, 

 

    

    

    

Dollar

    

% Increase

 

2023

2022

Change

(Decrease)

 

Sales:

 

  

 

  

 

  

 

  

Sales of Products

$

4,425,162

 

$

2,898,892

 

$

1,526,270

 

53

%

Sales of Engineering Services

 

265,673

 

108,866

 

156,807

 

144

%

 

  

 

  

 

  

 

  

Total Sales

 

4,690,835

 

3,007,758

 

1,683,077

 

56

%

 

  

 

  

 

  

 

  

Cost of Sales:

 

  

 

  

 

  

 

  

Cost of Sales - Products

 

3,303,979

 

2,451,890

 

852,089

 

35

%

Cost of Sales - Depreciation and Amortization

 

257,939

 

231,163

 

26,776

 

12

%

Cost of Sales - Engineering Services

 

156,531

 

59,296

 

97,235

 

164

%

 

  

 

  

 

  

 

  

Total Cost of Sales

 

3,718,449

 

2,742,349

 

976,100

 

36

%

 

  

 

  

 

  

 

  

Gross Profit

 

972,386

 

265,409

 

706,977

 

266

%

Gross Profit %

 

21

%  

9

%  

  

 

  

 

  

 

  

 

  

 

  

Operating Expenses:

 

  

 

  

 

  

 

  

Research and Development

 

2,836,552

 

2,996,144

 

(159,592)

 

(5)

%

Selling and Marketing

 

2,509,922

 

1,850,595

 

659,327

 

36

%

General and Administrative

 

4,260,322

 

5,039,949

 

(779,627)

 

(15)

%

Depreciation and Amortization

 

973,222

 

379,702

 

593,520

 

156

%

 

  

 

  

 

  

 

  

Loss from Operations

 

(9,607,632)

 

(10,000,981)

 

393,349

 

(4)

%

 

  

 

  

 

  

 

Other Income (Expense):

 

  

 

  

 

  

 

  

Investment Income

 

628,923

 

111,027

 

517,896

 

466

%

Income and Other Taxes

 

(35,420)

 

(31,326)

 

(4,094)

 

13

%

Foreign Exchange Loss

 

(30,791)

 

(100,388)

 

69,597

 

(69)

%

 

  

 

  

 

  

 

  

Total Other Income (Expense), Net

 

562,712

 

(20,687)

 

583,399

 

(2,820)

%

 

  

 

  

 

  

 

  

Loss Before Provision for Income Taxes

 

(9,044,920)

 

(10,021,668)

 

976,748

 

(10)

%

Provision for Income Taxes

 

 

 

 

%

 

  

 

  

 

  

 

  

Net Loss

$

(9,044,920)

$

(10,021,668)

$

976,748

 

(10)

%

17

Sales.   There was an increase in total sales for the three months ended June 30, 2023 compared to the same period in 2022 of $1,683,077 or 56%. The following table reflects the major components of our sales:

     

Three Months Ended

    

% of

    

Three Months Ended

    

% of

    

Dollar

    

% Increase

 

June 30, 2023

Total Sales

June 30, 2022

Total Sales

Change

(Decrease)

Sales of Products

$

4,425,162

 

94

%  

2,898,892

 

96

%  

$

1,526,270

 

53

%

Sales of Engineering Services

 

265,673

 

6

%  

 

108,866

 

4

%  

 

156,807

 

144

%

Total Sales

$

4,690,835

 

100

%  

$

3,007,758

 

100

%  

$

1,683,077

 

56

%

Sales of products increased by 53% for the three months ended June 30, 2023, compared to the same period in 2022. Smart glasses revenue was the primary driver of this increase as unit sales of our M400 product increased significantly.

Sales of engineering services for the three months ended June 30, 2023, was $265,673, as compared to $108,866 in the comparable 2022 period.

Cost of Sales and Gross Profit. Cost of product revenues and engineering services are comprised of materials, components, labor, warranty costs, freight costs, manufacturing overhead, software royalties, the depreciation for our tooling and manufacturing equipment, and amortization of software development costs related to the production of our products and rendering of engineering services. The following table reflects the components of our cost of goods sold:

    

Three Months Ended

    

As % Related

    

Three Months Ended

    

As % Related

    

Dollar

    

% Increase

June 30, 2023

Total Sales

June 30, 2022

Total Sales

Change

(Decrease)

Product Cost of Sales

$

2,940,253

63

%  

$

2,114,139

70

%  

$

826,114

39

%

Manufacturing Overhead - Unapplied

 

363,726

 

8

%  

337,751

 

11

%  

25,975

 

8

%

Depreciation and Amortization

257,939

5

%  

231,163

8

%  

26,776

12

%

Engineering Services Costs Sales

 

156,531

 

3

%  

59,296

 

2

%  

97,235

 

164

%

 

  

 

  

 

  

 

  

 

  

 

  

Total Cost of Sales

$

3,718,449

 

79

%  

$

2,742,349

 

91

%  

$

976,100

 

36

%

 

  

 

  

 

  

 

  

 

  

 

  

Gross Profit

$

972,386

 

21

%  

$

265,409

 

9

%  

$

706,977

 

266

%

For the three months ended June 30, 2023, gross profit from total sales was $972,386 or 21% as compared to $265,409 or 9% in the comparable period in 2022.

Unapplied manufacturing overhead costs, not already added in cost of sales, increased by $25,975 or 8% for the three months ended June 30, 2023 over the 2022 comparable period. Such costs, however, decreased as a percentage of total sales to 8% as compared to 11% in 2022. The increase in the net dollar amount of these unapplied overhead costs in the current period versus the prior period was primarily driven by upgrades to the opening balance of finished goods that were processed in the second quarter, despite our M400 production levels.

Depreciation and amortization expense in cost of sales increased by $26,776 or 12% because new manufacturing equipment was brought online in the second quarter as compared to the comparable 2022 period, when such activity was classified as construction-in-progress.

18

Research and Development.  Our research and development expenses consist primarily of compensation costs for personnel, including non-cash stock-based compensation expenses, third-party services, purchase of research supplies and materials, and consulting fees related to research and development. Software development expenses to determine technical feasibility before final development and ongoing maintenance are not capitalized and are included in research and development expenses.

Three Months Ended

% of

Three Months Ended

% of

Dollar

% Increase

June 30, 2023

Total Sales

June 30, 2022

Total Sales

Change

(Decrease)

Research and Development

$

2,836,552

 

60

%  

$

2,996,144

 

100

%  

$

(159,592)

 

(5)

%

Research and development expenses for the three months ended June 30, 2023, decreased by $159,592 or 5%, as compared to the comparable period in 2022. This decrease was largely due to a $192,929 reduction in external development expenses and consultants related to our new products; a decrease of $33,710 in supplies expenses; and partially offset by an increase of $76,569 in salary and benefits related expenses.

Selling and Marketing.   Selling and marketing expenses consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including non-cash stock-based compensation expense, consulting fees, public relations agency fees, website costs, and sales commissions paid to full-time staff and outside consultants.

Three Months Ended

% of

Three Months Ended

% of

Dollar

% Increase

    

June 30, 2023

    

Total Sales

June 30, 2022

    

Total Sales

Change

    

(Decrease)

Selling and Marketing

$

2,509,922

54

%  

$

1,850,595

62

%  

$

659,327

36

%

Selling and marketing expenses for the three months ended June 30, 2023, increased by $659,327 or 36%, as compared to the comparable period in 2022. This increase was largely due to a $519,746 increase in salary and benefits related expenses, driven by headcount increase; an increase of $87,179 in advertising and tradeshow expenses; and an increase of $68,258 in travel related expenses; partially offset by a decrease of $46,525 in website development and maintenance costs.

General and Administrative.  General and administrative expenses include professional fees, investor relations (IR) costs, salaries and related non-cash stock-based compensation, travel costs, and office and rental costs.

Three Months Ended

% of

Three Months Ended

% of

Dollar

% Increase

June 30, 2023

Total Sales

June 30, 2022

Total Sales

Change

(Decrease)

General and Administrative

$

4,260,322

 

91

%  

$

5,039,949

 

168

%  

$

(779,627)

 

(15)

%

General and administrative expenses for the three months ended June 30, 2023, decreased by $779,627 or 15%, as compared to the comparable period in 2022. This decrease was largely due to a decrease of $760,257 in salary and benefits related expenses, which was primarily driven by a decrease in non-cash stock-based compensation; and a decrease of $43,938 in accounting and tax services expenses; partially offset by an increase of $60,039 in travel related expenses.

Depreciation and Amortization.  Depreciation and amortization expense, not included in cost of sales, for the three months ended June 30, 2023, was $973,222, as compared to $379,702 in the comparable period in 2022, an increase of $593,520. The increase in depreciation and amortization expense is primarily due to the amortization of our technology license related to the Atomistic Agreements, which began on May 12, 2022.

19

Other Income (Expense), Net. Total other income was $562,712 for the three months ended June 30, 2023, as compared to other expense of $20,687 in the comparable period in 2022, an increase of $583,399. The overall increase in other income was primarily the result of an increase of $517,896 in investment income resulting from the recent rise in interest rates earned on the Company’s excess cash period-over-period; and a decrease in foreign exchange losses of $69,597.

Provision for Income Taxes. There was not a provision for income taxes in the respective three-month periods ending June 30, 2023, and 2022.

Comparison of Six Months Ended June 30, 2023 and 2022

The following table compares the Company’s consolidated statements of operations data for the six months ended June 30, 2023 and 2022:

Six Months Ended June 30, 

    

    

    

Dollar

    

% Increase

 

2023

2022

Change

(Decrease)

 

Sales:

 

  

 

  

 

  

 

  

Sales of Products

$

8,616,523

$

5,401,944

$

3,214,579

 

60

%

Sales of Engineering Services

 

265,673

 

108,866

 

156,807

 

144

%

Total Sales

 

8,882,196

 

5,510,810

 

3,371,386

 

61

%

Cost of Sales:

 

  

 

  

 

  

 

  

Cost of Sales - Products Sold

 

6,386,418

 

4,255,488

 

2,130,930

 

50

%

Cost of Sales - Depreciation and Amortization

 

490,855

 

454,949

 

35,906

 

8

%

Cost of Sales - Engineering Services

 

156,531

 

59,296

 

97,235

 

164

%

Total Cost of Sales

 

7,033,804

 

4,769,733

 

2,264,071

 

47

%

Gross Profit

 

1,848,392

 

741,077

 

1,107,315

 

149

%

Gross Profit %

 

21

%  

 

13

%  

 

  

 

  

Operating Expenses:

 

  

 

  

 

  

 

  

Research and Development

 

5,906,349

 

6,099,588

 

(193,239)

 

(3)

%

Selling and Marketing

 

5,049,581

 

3,914,584

 

1,134,997

 

29

%

General and Administrative

 

9,392,146

 

10,453,228

 

(1,061,082)

 

(10)

%

Depreciation and Amortization

 

1,937,487

 

638,946

 

1,298,541

 

203

%

Impairment of Patents and Trademarks

 

17,666

 

49,602

 

(31,936)

 

(64)

%

Loss from Operations

 

(20,454,837)

 

(20,414,871)

 

(39,966)

 

0

%

Other Income (Expense):

 

  

 

  

 

  

 

  

Investment Income

 

1,324,706

 

117,307

 

1,207,399

 

1,029

%

Income and Other Taxes

 

(123,215)

 

(78,959)

 

(44,256)

 

56

%

Foreign Exchange Loss

 

(32,157)

 

(151,145)

 

118,988

 

(79)

%

Total Other Income (Expense), Net

 

1,169,334

 

(112,797)

 

1,282,131

 

(1,137)

%

Net Loss

$

(19,285,503)

$

(20,527,668)

$

1,242,165

 

(6)

%

20

Sales.   There was an increase in total sales for the six months ended June 30, 2023, compared to the same period in 2022 of $3,371,386 or 61%. The following table reflects the major components of our sales:

    

Six Months Ended

    

% of

    

Six Months Ended

    

% of

    

Dollar

    

% Increase

June 30, 2023

Total Sales

June 30, 2022

Total Sales

Change

(Decrease)

Sales of Products

$

8,616,523

 

97

%  

$

5,401,944

 

98

%  

$

3,214,579

 

60

%

Sales of Engineering Services

 

265,673

 

3

%  

 

108,866

 

2

%  

 

156,807

 

144

%

Total Sales

$

8,882,196

 

100

%  

$

5,510,810

 

100

%  

$

3,371,386

 

61

%

Sales of products increased by 60% for the six months ended June 30, 2023, compared to the same period in 2022. Smart glasses revenue was the primary driver of this increase as unit sales of our M400 product increased significantly, partially offset by higher average sales discounts due to larger volume reseller sales compared to the comparable period in 2022.

Sales of engineering services for the six months ended June 30, 2023, was $265,673, as compared to $108,866 in the comparable 2022 period.

Cost of Sales and Gross Profit. Cost of product revenues and engineering services are comprised of materials, components, labor, warranty costs, freight costs, manufacturing overhead, software royalties, the depreciation for our tooling and manufacturing equipment, and amortization of software development costs related to the production of our products and rendering of engineering services. The following table reflects the components of our cost of goods sold:

Six Months Ended

% of

Six Months Ended

% of

Dollar

% Increase

    

June 30, 2023

    

Total Sales

    

June 30, 2022

    

Total Sales

    

Change

    

(Decrease)

Product Cost of Sales

$

5,487,776

 

62

%  

$

3,651,767

 

66

%  

$

1,836,009

 

50

%

Manufacturing Overhead - Unapplied

 

898,642

 

10

%  

 

734,604

 

13

%  

 

164,038

 

22

%

Depreciation and Amortization

 

490,855

 

6

%  

 

324,066

 

6

%  

 

166,789

 

51

%

Engineering Services Cost of Sales

 

156,531

 

2

%  

 

59,296

 

1

%  

 

97,235

 

164

%

Total Cost of Sales

7,033,804

 

79

%  

4,769,733

 

87

%  

2,264,071

 

47

%

Gross Profit

$

1,848,392

21

%

$

741,077

 

13

%

$

1,107,315

 

149

%

For the six months ended June 30, 2023, gross profit from total sales was $1,848,392 or 21% as compared to $741,077 or 13% in the comparable period in 2022.

Unapplied manufacturing overhead costs, not already added in cost of sales, increased by $164,038 or 22% for the six months ended June 30, 2023 over the 2022 comparable period, however, such costs decreased as a percentage of total sales to 10% as compared to 13% in 2022. The increase in the net dollar amount of these unapplied overhead costs in the current period versus the prior period was primarily driven by a combination of a supply chain issue that slowed some production in Q1 2023 and by upgrades to the opening balance of finished goods that were processed in the second quarter, despite our M400 production levels in the second quarter.

Depreciation and amortization expense in cost of sales, increased by $166,789 or 51% because new manufacturing equipment was brought online in the first half of 2023 as compared to the prior period, when such activity was classified as construction-in-progress.

21

Research and Development.  Our research and development expenses consist primarily of compensation costs for personnel, including non-cash stock-based compensation expenses, third-party services, purchase of research supplies and materials, and consulting fees related to research and development. Software development expenses to determine technical feasibility before final development and ongoing maintenance are not capitalized and are included in research and development expenses.

Six Months Ended

% of

Six Months Ended

% of

Dollar

% Increase

June 30, 2023

Total Sales

June 30, 2022

Total Sales

Change

(Decrease)

Research and Development

$

5,906,349

 

66

%  

$

6,099,588

 

111

%  

$

(193,239)

 

(3)

%

Research and development expenses for the six months ended June 30, 2023, decreased by $193,239 or 3%, as compared to the comparable period in 2022. This decrease was largely due to a $141,297 reduction in external development expenses and consultants related to our new products; a decrease of $79,059 in recruiting and hiring expenses; and a decrease of $39,897 in supplies expenses; partially offset by an increase of $72,099 in salary and benefits related expenses.

Selling and Marketing.   Selling and marketing expenses consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including non-cash stock-based compensation expense, consulting fees, public relations agency fees, website costs, and sales commissions paid to full-time staff and outside consultants.

Six Months Ended

% of

Six Months Ended

% of

Dollar

% Increase

June 30, 2023

Total Sales

June 30, 2022

Total Sales

Change

(Decrease)

Selling and Marketing

$

5,049,581

 

57

%  

$

3,914,584

 

71

%  

$

1,134,997

 

29

%

Selling and marketing expenses for the six months ended June 30, 2023, increased by $1,134,997 or 29%, as compared to the comparable period in 2022. This increase was largely due to a $964,021 increase in salary and benefits related expenses, driven by headcount increases; an increase of $160,450 in travel related expenses; and an increase of $53,635 in advertising and tradeshow expenses; partially offset by a decrease of $42,523 in website development and maintenance costs.

General and Administrative.  General and administrative expenses include professional fees, investor relations (IR) costs, salaries and related non-cash stock-based compensation, travel costs, office and rental costs.

Six Months Ended

% of

Six Months Ended

% of

Dollar

% Increase

June 30, 2023

Total Sales

June 30, 2022

Total Sales

Change

(Decrease)

General and Administrative

$

9,392,146

 

106

%  

$

10,453,228

 

190

%  

$

(1,061,082)

 

(10)

%

General and administrative expenses for the six months ended June 30, 2023, decreased by $1,061,082 or 10%, as compared to the comparable period in 2022. This decrease was largely due to a decrease of $1,379,618 in salary and benefits related expenses, which was primarily driven by a decrease in non-cash stock-based compensation; a decrease of $108,555 in external accounting and tax services expenses; and a $47,255 decrease in legal expenses; partially offset by an increase of $193,176 in shareholder and IR related expenses; an increase of $141,817 in consulting fees; an increase of $79,639 in travel related expenses; and an increase of $49,024 in insurance premiums.

Depreciation and Amortization.  Depreciation and amortization expense, not included in cost of sales, for the six months ended June 30, 2023, was $1,937,487, as compared to $638,946 in the comparable period in 2022, an increase of $1,298,541. The increase in depreciation and amortization expense is primarily due to the amortization of our technology license related to the Atomistic Agreements, which began on May 12, 2022.

22

Other Income (Expense), Net. Total other income was $1,169,334 for the six months ended June 30, 2023, as compared to other expense of $112,797 in the comparable period in 2022, an increase of $1,282,131. The overall increase in other income was primarily the result of an increase of $1,207,399 in investment income resulting from the recent rise in interest rates earned on the Company’s excess cash period over period; and a decrease in foreign exchange losses of $118,988; partially offset by an increase of $44,256 in income and other taxes.

Provision for Income Taxes. There was not a provision for income taxes in the respective six-month periods ending June 30, 2023, and 2022.

Liquidity and Capital Resources

Capital Resources: As of June 30, 2023, we had cash and cash equivalents of $48,582,005, a decrease of $23,981,938 from $72,563,943 as of December 31, 2022.

As of June 30, 2023, we had current assets of $68,321,314 as compared to current liabilities of $6,825,090 which resulted in a positive working capital position of $61,496,224. As of December 31, 2022, we had a working capital position of $75,963,883. Our current liabilities are comprised principally of accounts payable, accrued expenses, licensing fee commitments, and operating lease right-of-use liabilities.

Summary of Cash Flow:

The following table summarizes our select cash flows for the six months ended:

June 30, 

June 30, 

    

2023

    

2022

Net Cash Provided by (used in)

 

  

 

  

Operating Activities

$

(12,085,707)

$ (11,016,909)

Investing Activities

 

(11,440,020)

 

(8,402,617)

Financing Activities

 

(456,211)

 

(202,552)

During the six months ended June 30, 2023, we used $12,085,707 of cash for operating activities. Net changes in working capital items were $2,226,731 for the six months ended June 30, 2023, with the largest factors resulting from a $3,027,270 increase in trade accounts receivables and accrued revenue in excess of billings, partially offset by receipt of $466,705 for our Employee Retention Credit, which was filed with the IRS in November 2022; a $562,818 decrease in inventory and vendor prepayments; and a $232,619 decrease in trade accounts payable and accrued expenses. For the six months ended June 30, 2022, we used a total of $11,016,909 in cash for operating activities.

During the six months ended June 30, 2023, we used $11,440,020 of cash for investing activities, which included $8,000,000 in payments made towards our technology license fee commitment with Atomistic, as discussed in Note 6, $2,774,513 for purchases of manufacturing equipment and leasehold improvement expenditures primarily related to our waveguide expansion project; $340,507 in patent and trademark expenditures; a further investment of $125,000 in the purchase of software operating license upgrades for our smart glasses platform; and an additional $200,000 of investments in private corporations as discussed in Note 7. For the six months ended June 30, 2022, we used a total of $8,402,617 in cash for investing activities.

During the six months ending June 30, 2023, we used $456,211 in net cash for financing activities, which included $14,546 received for stock option exercises, which was offset by $470,757 expended for share repurchases under our Share Buyback Program that expired on March 2, 2023. For the six months ended June 30, 2022, we used $202,552 in net cash for financing activities.

As of June 30, 2023, the Company does not have any current or long-term debt obligations outstanding other than licensing fee commitments totaling $3,500,000, which are all current.

23

The Company’s cash requirements are primarily for funding operating losses, working capital, research and development, capital expenditures, and licensing fee commitments. We incurred a net loss for the six months ended June 30, 2023, of $19,285,503 (of which $6,500,261 was related to non-cash stock-based compensation) and for the years ended December 31, 2022, and 2021 of $40,763,573 (of which $15,775,553 was related to non-cash stock-based compensation) and $40,377,160 (of which $17,302,833 was related to non-cash stock-based compensation), respectively. The Company has an accumulated deficit of $263,507,583 as of June 30, 2023.

Our operations have historically been financed primarily through net proceeds from the sale of our equity securities. As of June 30, 2023, our principal sources of liquidity consisted of cash and cash equivalents of $48,582,005.

Forward Looking Statements

This quarterly report includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to, statements concerning:

trends in our operating expenses, including personnel costs, research and development expense, sales and marketing expense, and general and administrative expense;
the effect of competitors and competition in our markets;
our wearable smart glasses products and their market acceptance and future potential;
our ability to develop, timely introduce, and effectively manage the introduction of new products and services or improve our existing products and services;
expected technological advances by us or by third parties and our ability to leverage them;
our ability to attract and retain customers;
our ability to accurately forecast consumer demand and adequately manage our inventory;
our ability to deliver an adequate supply of product to meet demand;
our ability to maintain and promote our brand and expand brand awareness;
our ability to detect, prevent, or fix defects in our products;
our reliance on third-party suppliers, contract manufacturers and logistics providers and our limited control over such parties;
trends in revenue, costs of revenue, and gross margin and our possible or assumed future results of operations;
our ability to attract and retain highly skilled employees;
the impact of foreign currency exchange rates;
the effect of future regulations;
the sufficiency of our existing cash and cash equivalent balances and cash flow from operations to meet our working capital and capital expenditure needs for at least the next twelve (12) months; and
general market, political, economic, business and public health conditions.

24

All statements in this quarterly report that are not historical facts are forward-looking statements. We may, in some cases, use terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes to identify forward-looking statements.

All such forward-looking statements are subject to certain risks and uncertainties and should be evaluated in light of important risk factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These risk factors include, but are not limited to, those described in “Risk Factors” in this report and under Item 1A and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2022, and other filings we make with the Securities and Exchange Commission and the following: business and economic conditions, rapid technological changes accompanied by frequent new product introductions, competitive pressures, dependence on key customers, inability to gauge order flows from customers, fluctuations in quarterly and annual results, the reliance on a limited number of third-party suppliers, limitations of our manufacturing capacity and arrangements, the protection of our proprietary technology, the effects of pending or threatened litigation, the dependence on key personnel, changes in critical accounting estimates, potential impairments related to investments, foreign regulations, liquidity issues, and potential material weaknesses in internal control over financial reporting. Further, during weak or uncertain economic periods, customers may delay the placement of their orders. These factors often result in a substantial portion of our revenue being derived from orders placed within a quarter and shipped in the final month of the same quarter.

We caution readers to carefully consider such factors. Many of these factors are beyond our control. In addition, any forward-looking statements represent our estimates only as of the date they are made and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, except as may be required under applicable securities laws, we specifically disclaim any obligation to do so.

Item 3.Quantitative and Qualitative Disclosures about Market Risk

We invest our excess cash in high-quality short-term corporate debt instruments, which bear lower levels of relative risk. We believe that the effect, if any, of possible near-term changes in interest rates on our financial position, results of operations, and cash flows should not be material to our cash flows or income. It is possible that interest rate movements would increase our unrealized gain or loss on interest rate securities. We are exposed to changes in foreign currency exchange rates primarily through transaction gains and losses as a result of non-U.S. dollar denominated cash flows related to business activities in Japan and Europe. We do not currently hedge our foreign currency exchange rate risk. We estimate that any market risk associated with our international operations is unlikely to have a material adverse effect on our business, financial condition or results of operation.

Item 4.Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management, with the participation of the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has performed an evaluation of the effectiveness of our disclosure controls and procedures that are defined in Rule 13a-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report. This evaluation included consideration of the controls, processes, and procedures that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is properly recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our management, including our CEO and CFO, concluded that our disclosure controls and procedures were effective at June 30, 2023.

Changes in Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as defined in 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) that occurred during the Company’s most recent fiscal

25

quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Part II. OTHER INFORMATION

Item 1.Legal Proceedings

We are not currently involved in any actual or pending legal proceedings or litigation that we consider to be material, and we are not aware of any such proceedings contemplated by or against us or involving our property.

Item 1A.Risk Factors

In addition to the other information set forth in this report you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes from those risk factors. The risks discussed in our 2022 Annual Report could materially affect our business, financial condition and future results.

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

Sale of Unregistered Securities

During the three months ended June 30, 2023, the Company issued 96,525 shares of common stock to its independent board members as part of their annual retainer for services covering the period of July 2023 to June 2024. In connection with the foregoing, the Company relied upon the exemption from registration for transactions not involving a public offering.

Purchase of Equity Securities: - none

Item 3.Defaults Upon Senior Securities

None

Item 4.Mine Safety Disclosures

Not Applicable

Item 5.Other Information

None

26

Item 6.Exhibits

Exhibit No.

    

Description

 

31.1

Certification of the Chief Executive Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

31.2

Certification of the Chief Financial Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

32.1

Certification of the Chief Executive Officer of the Registrant pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

 

 

32.2

Certification of the Chief Financial Officer of the Registrant pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

 

 

101

Inline XBRL Document set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*

* Filed herewith.

** Furnished herewith

.

27

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

VUZIX CORPORATION

 

 

 

Date: August 8, 2023

By:

/s/ Paul Travers

 

 

Paul Travers

 

 

President, Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

Date: August 8, 2023

By:

/s/ Grant Russell

 

 

Grant Russell

 

 

Executive Vice President and Chief Financial

 

 

Officer

 

 

(Principal Financial and Accounting Officer)

28

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Paul Travers, certify that:

1.     I have reviewed this quarterly report on Form 10-Q of Vuzix Corporation;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

(c)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2023

/s/ Paul Travers

 

Paul Travers

 

President and Chief Executive Officer


Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Grant Russell, certify that:

1.     I have reviewed this quarterly report on Form 10-Q of Vuzix Corporation;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

(c)   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2023

/s/ Grant Russell

 

Grant Russell

 

Executive Vice President and Chief Financial Officer


Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Vuzix Corporation (“Vuzix”) on Form 10-Q for the quarterly period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Travers, President and Chief Executive Officer of Vuzix, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Vuzix.

 

/s/ Paul Travers

 

Paul Travers

 

President and Chief Executive Officer

 

 

Date: August 8, 2023

 


Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Vuzix Corporation (“Vuzix”) on Form 10-Q for the quarterly period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Grant Russell, Executive Vice President and Chief Financial Officer of Vuzix, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Vuzix.

 

/s/ Grant Russell

 

Grant Russell

 

Executive Vice President and Chief Financial Officer

 

 

Date: August 8, 2023

 


v3.23.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2023
Aug. 08, 2023
Document and Entity Information    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 001-35955  
Entity Registrant Name Vuzix Corp  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 04-3392453  
Entity Address, Address Line One 25 Hendrix Road, Suite A  
Entity Address, City or Town West Henrietta  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 14586  
City Area Code 585  
Local Phone Number 359-5900  
Title of 12(b) Security Common Stock, par value $0.001  
Trading Symbol VUZI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   63,319,217
Entity Central Index Key 0001463972  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Amendment Flag false  
v3.23.2
CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current Assets    
Cash and Cash Equivalents $ 48,582,005 $ 72,563,943
Accounts Receivable, Net 6,545,608 3,558,971
Accrued Revenues in Excess of Billings 309,762 269,129
Employee Retention Credit Receivable   466,705
Inventories, Net 10,870,166 11,267,969
Manufacturing Vendor Prepayments 353,399 998,671
Prepaid Expenses and Other Assets 1,660,374 2,115,853
Total Current Assets 68,321,314 91,241,241
Long-Term Assets    
Fixed Assets, Net 6,814,005 3,878,505
Operating Lease Right-of-Use Asset 628,131 956,165
Patents and Trademarks, Net 2,438,299 2,220,094
Technology Licenses, Net 28,504,870 30,158,689
Intangible Asset, Net 605,453 675,313
Goodwill 1,601,400 1,601,400
Other Assets, Net 1,649,132 1,581,143
Total Assets 110,562,604 132,312,550
Current Liabilities    
Accounts Payable 1,620,490 1,211,747
Unearned Revenue 107,043 29,064
Accrued Expenses 1,029,177 1,670,539
Licensing Fees Commitment 3,500,000 11,500,000
Income and Other Taxes Payable 138,959 214,997
Operating Lease Right-of-Use Liability 429,421 651,011
Total Current Liabilities 6,825,090 15,277,358
Long-Term Liabilities    
Operating Lease Right-of-Use Liability 198,710 305,154
Total Liabilities 7,023,800 15,582,512
Stockholders' Equity    
Common Stock - $0.001 Par Value, 100,000,000 shares authorized; 63,898,889 shares issued and 63,319,217 shares outstanding as of June 30, 2023 and 63,783,779 shares issued and 63,319,107 shares outstanding as of December 31, 2022. 63,899 63,783
Additional Paid-in Capital 369,072,625 362,507,715
Accumulated Deficit (263,121,219) (243,835,716)
Treasury Stock, at cost, 579,672 shares as of June 30, 2023 and 464,672 shares as of December 31, 2022. (2,476,501) (2,005,744)
Total Stockholders' Equity 103,538,804 116,730,038
Total Liabilities and Stockholders' Equity $ 110,562,604 $ 132,312,550
v3.23.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
CONSOLIDATED BALANCE SHEETS    
Common Stock, Par Value $ 0.001 $ 0.001
Common Stock, Shares Authorized 100,000,000 100,000,000
Common Stock, Shares Issued 63,898,889 63,783,779
Common Stock, Shares Outstanding 63,319,217 63,319,107
Common shares held in treasury 579,672 464,672
v3.23.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Treasury Stock
Total
Balance at Dec. 31, 2021 $ 63,672 $ 346,736,397 $ (203,072,143)   $ 143,727,926
Balance (in shares) at Dec. 31, 2021 63,672,268        
Stock-Based Compensation Expense $ 289 8,538,153     8,538,442
Stock-Based Compensation Expense (in shares) 288,650        
Stock Option Exercises $ 65 48,440     48,505
Stock Option Exercises (in shares) 64,722        
Purchases of Treasury Stock       $ (251,057) (251,057)
Purchases of Treasury Stock (in Shares)       (36,685)  
Net Loss     (20,527,668)   (20,527,668)
Balance at Jun. 30, 2022 $ 64,026 355,322,990 (223,599,811) $ (251,057) 131,536,148
Balance (in shares) at Jun. 30, 2022 64,025,640     (36,685)  
Balance at Mar. 31, 2022 $ 63,705 350,721,326 (213,578,143) $ (251,057) 136,955,831
Balance (in shares) at Mar. 31, 2022 63,704,626     (36,685)  
Stock-Based Compensation Expense $ 289 4,582,414     4,582,703
Stock-Based Compensation Expense (in shares) 288,650        
Stock Option Exercises $ 32 19,250     19,282
Stock Option Exercises (in shares) 32,364        
Net Loss     (10,021,668)   (10,021,668)
Balance at Jun. 30, 2022 $ 64,026 355,322,990 (223,599,811) $ (251,057) 131,536,148
Balance (in shares) at Jun. 30, 2022 64,025,640     (36,685)  
Balance at Dec. 31, 2022 $ 63,783 362,507,715 (243,835,716) $ (2,005,744) $ 116,730,038
Balance (in shares) at Dec. 31, 2022 63,783,779     (464,672)  
Purchases of Treasury Stock (in Shares)         115,000
Balance at Mar. 31, 2023 $ 63,787 365,868,487 (254,076,299) $ (2,476,501) $ 109,379,474
Balance (in shares) at Mar. 31, 2023 63,787,858     (579,672)  
Balance at Dec. 31, 2022 $ 63,783 362,507,715 (243,835,716) $ (2,005,744) 116,730,038
Balance (in shares) at Dec. 31, 2022 63,783,779     (464,672)  
Stock-Based Compensation Expense $ 97 6,550,382     6,550,479
Stock-Based Compensation Expense (in shares) 96,525        
Stock Option Exercises $ 19 14,528     14,547
Stock Option Exercises (in shares) 18,585        
Purchases of Treasury Stock       $ (470,757) (470,757)
Purchases of Treasury Stock (in Shares)       (115,000)  
Net Loss     (19,285,503)   (19,285,503)
Balance at Jun. 30, 2023 $ 63,899 369,072,625 (263,121,219) $ (2,476,501) 103,538,804
Balance (in shares) at Jun. 30, 2023 63,898,889     (579,672)  
Balance at Mar. 31, 2023 $ 63,787 365,868,487 (254,076,299) $ (2,476,501) 109,379,474
Balance (in shares) at Mar. 31, 2023 63,787,858     (579,672)  
Stock-Based Compensation Expense $ 97 3,189,606     3,189,703
Stock-Based Compensation Expense (in shares) 96,525        
Stock Option Exercises $ 15 14,532     14,547
Stock Option Exercises (in shares) 14,506        
Net Loss     (9,044,920)   (9,044,920)
Balance at Jun. 30, 2023 $ 63,899 $ 369,072,625 $ (263,121,219) $ (2,476,501) $ 103,538,804
Balance (in shares) at Jun. 30, 2023 63,898,889     (579,672)  
v3.23.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Sales:        
Total Sales $ 4,690,835 $ 3,007,758 $ 8,882,196 $ 5,510,810
Cost of Sales:        
Cost of Sales - Depreciation and Amortization 257,939 231,163 490,855 454,949
Total Cost of Sales 3,718,449 2,742,349 7,033,804 4,769,733
Gross Profit 972,386 265,409 1,848,392 741,077
Operating Expenses:        
Research and Development 2,836,552 2,996,144 5,906,349 6,099,588
Selling and Marketing 2,509,922 1,850,595 5,049,581 3,914,584
General and Administrative 4,260,322 5,039,949 9,392,146 10,453,228
Depreciation and Amortization 973,222 379,702 1,937,487 638,946
Impairment of Patents and Trademarks     17,666 49,602
Total Operating Expenses 10,580,018 10,266,390 22,303,229 21,155,948
Loss From Operations (9,607,632) (10,000,981) (20,454,837) (20,414,871)
Other Income (Expense):        
Investment Income 628,923 111,027 1,324,706 117,307
Income and Other Taxes (35,420) (31,326) (123,215) (78,959)
Foreign Exchange Loss (30,791) (100,388) (32,157) (151,145)
Total Other Income (Expense), Net 562,712 (20,687) 1,169,334 (112,797)
Loss Before Provision for Income Taxes (9,044,920) (10,021,668) (19,285,503) (20,527,668)
Net Loss $ (9,044,920) $ (10,021,668) $ (19,285,503) $ (20,527,668)
Basic Loss per Common Share $ (0.14) $ (0.16) $ (0.31) $ (0.32)
Diluted Loss per Common Share $ (0.14) $ (0.16) $ (0.31) $ (0.32)
Weighted-average Shares Outstanding - Basic 63,230,859 63,739,863 63,223,768 63,717,618
Weighted-average Shares Outstanding - Diluted 63,230,859 63,739,863 63,223,768 63,717,618
Sales of Products        
Sales:        
Total Sales $ 4,425,162 $ 2,898,892 $ 8,616,523 $ 5,401,944
Cost of Sales:        
Cost of Sales 3,303,979 2,451,890 6,386,418 4,255,488
Sales of Engineering Services        
Sales:        
Total Sales 265,673 108,866 265,673 108,866
Cost of Sales:        
Cost of Sales $ 156,531 $ 59,296 $ 156,531 $ 59,296
v3.23.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash Flows from Operating Activities    
Net Loss $ (19,285,503) $ (20,527,668)
Non-Cash Adjustments    
Depreciation and Amortization 2,428,342 1,093,895
Stock-Based Compensation 6,500,261 8,200,774
Impairment of Patents and Trademarks 17,666 49,602
Change in Inventory Reserve for Obsolescence 480,258  
(Increase) Decrease in Operating Assets    
Accounts Receivable (2,986,637) 678,523
Accrued Revenues in Excess of Billings (40,633) (108,866)
Employee Retention Credit Receivable 466,705  
Inventories (82,454) 359,893
Manufacturing Vendor Prepayments 645,272 (654,569)
Prepaid Expenses and Other Assets 1,692 492,599
Increase (Decrease) in Operating Liabilities    
Accounts Payable 408,743 (732,813)
Accrued Expenses (641,362) 195,276
Unearned Revenue 77,980 12,829
Income and Other Taxes Payable (76,037) (76,384)
Net Cash Flows Used in Operating Activities (12,085,707) (11,016,909)
Cash Flows from Investing Activities    
Purchases of Fixed Assets (2,774,513) (3,504,931)
Investments in Patents and Trademarks (340,507) (272,686)
Investments in Licenses, Intangibles and Other Assets (8,000,000) (4,625,000)
Investments in Software Development (125,000)  
Investments in Other Assets (200,000)  
Net Cash Flows Used in Investing Activities (11,440,020) (8,402,617)
Cash Flows from (used) Financing Activities    
Proceeds from Exercise of Stock Options 14,546 48,505
Purchases of Treasury Stock (470,757) (251,057)
Net Cash Flows Used in Financing Activities (456,211) (202,552)
Net Decrease in Cash and Cash Equivalents (23,981,938) (19,622,078)
Cash and Cash Equivalents - Beginning of Period 72,563,943 120,203,873
Cash and Cash Equivalents - End of Period 48,582,005 100,581,795
Supplemental Disclosures    
Unamortized Common Stock Expense included in Prepaid Expenses and Other Assets 1,335,307 1,223,691
Non-Cash Investment in Licenses 3,500,000 10,500,000
Stock-Based Compensation Expense - Expensed less Previously Issued $ (50,218) $ (337,379)
v3.23.2
Basis of Presentation
6 Months Ended
Jun. 30, 2023
Basis of Presentation  
Basis of Presentation

Note 1 – Basis of Presentation

The accompanying unaudited consolidated financial statements of Vuzix Corporation (“the Company” or “Vuzix”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, the unaudited consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Certain re-classifications have been made to prior comparable periods to conform with current reporting impacting Costs of Sales, Gross Profit and Depreciation and Amortization. The results of the Company’s operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results of the Company’s operations for the full fiscal year or any other period.

The accompanying interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto of the Company as of and for the year ended December 31, 2022, as reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2023.

Re-classification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year’s presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Operations for the three and six months ended June 30, 2022, to reclassify depreciation expense related to our manufacturing operations from the amounts of reported depreciation and amortization expenses originally included in Operating Expenses. This change in classification does not affect previously reported Net Loss or reported Cash Flows Used in Operating Activities in the Consolidated Statements of Cash Flows or Consolidated Balance Sheets. The below table is a summary of the impact of these re-classifications:

For the Three Months Ended June 30, 2022

For the Six Months Ended June, 2022

As Previously

As Previously

Condensed Statement of Operations

    

Presented

    

Re-classification

    

Revised

    

Presented

    

Re-classification

    

Revised

Total Sales

$

3,007,758

$

$

3,007,758

$

5,510,810

$

$

5,510,810

Cost of Sales - Products Sold

2,522,674

(70,784)

2,451,890

4,386,371

(130,883)

4,255,488

Cost of Sales - Depreciation and Amortization

231,163

231,163

454,949

454,949

Cost of Sales - Engineering Services

59,296

59,296

59,296

59,296

Gross Profit

425,788

160,379

265,409

1,065,143

324,066

741,077

Operating Expenses:

Research and Development

2,996,144

2,996,144

6,099,588

6,099,588

Selling and Marketing

1,850,595

1,850,595

3,914,584

3,914,584

General and Administrative

5,039,949

5,039,949

10,453,228

10,453,228

Depreciation and Amortization

540,081

(160,379)

379,702

963,012

(324,066)

638,946

Impairment of Patents and Trademarks

49,602

49,602

Total Operating Expenses

10,426,769

(160,379)

10,266,390

21,480,014

(324,066)

21,155,948

Loss From Operations

 

(10,000,981)

 

 

(10,000,981)

 

(20,414,871)

 

 

(20,414,871)

Total Other Expense, Net

(20,687)

(20,687)

(112,797)

(112,797)

Net Loss

$

(10,021,668)

$

$

(10,021,668)

$

(20,527,668)

$

$

(20,527,668)

Customer Concentrations

For the three months ended June 30, 2023, one customer represented 75% of total product revenue. For the three months ended June 30, 2022, one customer represented 45% of total product revenue.

For the six months ended June 30, 2023, two customers represented 40% and 35% of total product revenue. For the six months ended June 30, 2022, one customer represented 24% of total product revenue.

As of June 30, 2023, two customers represented 58% and 23% of accounts receivable. As of December 31, 2022, one customer represented 26% of accounts receivable.

Treasury Stock

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains and losses on the subsequent re-issuance of shares will be credited or charged to paid-in capital in excess of par value using the average-cost method.

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). ASU 2016-13 provides for a new impairment model which requires measurement and recognition of expected credit losses for most financial assets and certain other instruments, including but not limited to, accounts receivable. The Company adopted ASU 2016-13 effective on January 1, 2023. The adoption of this standard did not have a material impact on our consolidated financial statements.

v3.23.2
Revenue Recognition and Contracts with Customers
6 Months Ended
Jun. 30, 2023
Revenue Recognition and Contracts with Customers  
Revenue Recognition and Contracts with Customers

Note 2 – Revenue Recognition and Contracts with Customers

Disaggregated Revenue

The Company’s total revenue was comprised of two major product lines: Smart Glasses Sales and Engineering Services. The following table summarizes the revenue recognized by major product line:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2023

    

2022

    

2023

    

2022

Revenues

 

  

 

  

 

  

 

  

Products Sales

$

4,425,162

$

2,898,892

$

8,616,523

$

5,401,944

Engineering Services

 

265,673

 

108,866

 

265,673

 

108,866

Total Revenue

$

4,690,835

$

3,007,758

$

8,882,196

$

5,510,810

Significant Judgments

Under Topic 606 “Revenue from Contracts with Customers”, we use judgments that could potentially impact both the timing of our satisfaction of performance obligations and our determination of transaction prices used in determining revenue recognized by major product line. Such judgments include considerations in determining our transaction prices and when our performance obligations are satisfied for our standard product sales that include an end-user 30-day right to return if not satisfied with product and general payment terms that are between Net 30 and 60 days. For our engineering services, performance obligations are recognized over time using the input method and the estimated costs to complete each project are considered significant judgments.

Performance Obligations

Revenues from our performance obligations are typically satisfied at a point-in-time for Smart Glasses, Waveguides and Display Engines, and our OEM Products, which are recognized when the customer obtains control and ownership, which is generally upon shipment. The Company considers shipping and handling activities performed to be fulfillment activities and not a separate performance obligation. The Company also records revenue for performance obligations relating to our engineering services over time by using the input method measuring progress toward satisfying the performance obligations. Satisfaction of our performance obligations related to our engineering services is

measured by the Company’s costs incurred as a percentage of total expected costs to project completion as the inputs of actual costs incurred by the Company are directly correlated with progress toward completing the contract. As such, the Company believes that our methodologies for recognizing revenue over time for our engineering services correlate directly with the transfer of control of the underlying assets to our customers.

Our standard product sales include a twelve (12) month assurance-type product warranty. In the case of certain of our OEM products and waveguide sales, some include a standard product warranty of up to eighteen (18) months to allow distribution channels to offer the end customer a full twelve (12) months of coverage. We offer extended warranties to customers, which extend the standard product warranty on product sales for an additional twelve (12) month period. All revenue related to extended product warranty sales is deferred and recognized over the extended warranty period. Our engineering services contracts vary from contract to contract but typically include payment terms of Net 30 days from the date of billing, subject to an agreed upon customer acceptance period.

The following table presents a summary of the Company’s sales by revenue recognition method as a percentage of total net sales for the six months ended June 30:

    

% of Total Net Sales

2023

 

2022

 

Point-in-Time

 

97%

%

98%

%

Over Time – Input Method

 

3%

%

2%

%

Total

 

100%

%

100%

%

Remaining Performance Obligations

As of June 30, 2023, the Company had approximately $80,000 of remaining performance obligations under a current waveguide development project, which represents the remainder of the total transaction price of approximately $800,000 under this development agreement, which commenced in 2022, less revenue recognized under percentage of completion to date. The Company expects to recognize the remaining revenue related to this project in the third quarter of 2023. Revenues earned less amounts invoiced at June 30, 2023 in the amount of $309,762 are reflected as Accrued Revenues in Excess of Billings in the accompanying Consolidated Balance Sheet.

The Company had no material outstanding performance obligations related to product sales, other than its standard product warranty.

v3.23.2
Loss Per Share
6 Months Ended
Jun. 30, 2023
Loss Per Share  
Loss Per Share

Note 3 – Loss Per Share

Basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution from the assumed exercise of stock options. During periods of net loss, all common stock equivalents are excluded from the diluted EPS calculation because they are anti-dilutive. Since the Company reported a net loss for the three and six months ended June 30, 2023 and 2022, the calculation for basic and diluted earnings per share is considered to be the same, as the impact of potential common shares is anti-dilutive. As of June 30, 2023 and 2022, there were 8,658,642 and 8,528,668 common stock share equivalents, respectively, potentially exercisable or issuable under conversion or exercise of stock options that could dilute basic earnings per share in the future.

v3.23.2
Inventories, Net
6 Months Ended
Jun. 30, 2023
Inventories, Net  
Inventories, Net

Note 4 – Inventories, Net

Inventories are stated at the lower of cost and net realizable value, and consisted of the following:

June 30, 

December 31, 

    

2023

    

2022

Purchased Parts and Components

$

9,780,977

$

10,399,527

Work-in-Process

 

518,460

 

344,242

Finished Goods

 

2,468,476

 

1,941,689

Less: Reserve for Obsolescence

 

(1,897,747)

 

(1,417,489)

Inventories, Net

$

10,870,166

$

11,267,969

v3.23.2
Fixed Assets
6 Months Ended
Jun. 30, 2023
Fixed Assets  
Fixed Assets

Note 5 – Fixed Assets

Fixed Assets consisted of the following:

June 30, 

December 31, 

    

2023

    

2022

Tooling and Manufacturing Equipment

$

8,866,022

$

6,065,445

Leaseholds

 

1,472,898

 

826,329

Computers and Purchased Software

 

789,036

 

760,256

Furniture and Equipment

 

2,513,575

 

2,487,650

 

13,641,531

 

10,139,680

Less: Accumulated Depreciation

 

(6,827,526)

 

(6,261,175)

Fixed Assets, Net

$

6,814,005

$

3,878,505

During the six months ended June 30, 2023, the Company invested $2,774,513 in tooling and manufacturing equipment and leasehold improvements, mostly attributable to the Company’s new waveguide expansion project. Construction on the Company’s new facility began late in December 2022 and the Company expects the construction to be completed by the end of September 2023.

Total depreciation expense for fixed assets, not included in cost of sales, for the three months ended June 30, 2023, and 2022 was $111,934 and $111,943, respectively. Total depreciation expense for fixed assets, not included in cost of sales, for the six months ended June 30, 2023, and 2022 was $214,385 and $229,029, respectively.

v3.23.2
Technology Licenses, Net
6 Months Ended
Jun. 30, 2023
Technology Licenses, Net  
Technology Licenses, Net

Note 6 – Technology Licenses, Net

June 30, 

December 31, 

    

2023

    

2022

Licenses

$

32,443,356

$

2,443,356

Additions

 

 

30,000,000

Less: Accumulated Amortization

 

(3,938,486)

 

(2,284,667)

Licenses, Net

$

28,504,870

$

30,158,689

Total amortization expense related to technology licenses for the three months ended June 30, 2023 and 2022 was $826,984 and $244,201, respectively. Total amortization expense related to technology licenses for the six months ended June 30, 2023, and 2022 was $1,653,868 and $300,901, respectively.

The Company signed a series of agreements with Atomistic SAS in 2022, which provided for an exclusive license of key micro LED technology for cash commitments totaling $30 million along with performance-based cash and

equity issuance commitments to be made by the Company relating to the certain deliverables and the achievement of milestones by Atomistic, as further discussed in Note 10 – Capital Stock.

These intangible technology license assets are to be amortized over a ten-year period. As of June 30, 2023, there is a remaining funding commitment of $3,500,000 associated with these licenses, that will be paid over the next six months.

v3.23.2
Other Assets
6 Months Ended
Jun. 30, 2023
Other Assets  
Other Assets

Note 7 - Other Assets

June 30,

December 31, 

    

2023

    

2022

Private Corporation Investments

$

450,000

$

450,000

Additions

200,000

Total Private Corporation Investments (at cost)

650,000

450,000

Software Development Costs

875,000

750,000

Additions

125,000

125,000

Less: Accumulated Amortization

(513,889)

(375,000)

Software Development Costs, Net

486,111

500,000

Unamortized Common Stock Expense included in Long-Term Prepaid Expenses

513,021

631,143

Total Other Assets

$

1,649,132

$

1,581,143

In 2021, the Company acquired, for a purchase price of $200,000, an ownership interest of 3%, in the form of preferred stock, in a private corporation developing smart glasses software for use by retailers in the stock keeping of inventory, amongst other uses. In the six months ended June 30, 2023, the Company purchased an additional $100,000 of preferred stock in this corporation through a subsequent round of funding in order to retain a 2% ownership interest.

In June 2023, the Company purchased $100,000 of preferred stock, along with warrants, in a UK-based public company developing new semiconductor materials for displays. The investment represents less than a 1% ownership interest.

During 2020, the Company invested $500,000 in Android operating systems upgrades for its CPU platform used in its M400 and M4000 products. This upgrade was finished and placed into service in the beginning of the fourth quarter of 2020.  This capitalized asset is being amortized on a straight-line basis over its expected product life cycle of thirty-six (36) months, which began on October 1, 2020. In October 2021, the Company invested $250,000 and in the first quarter of 2022 the Company invested an additional $125,000 for further Android operating systems version upgrades to the CPU platform it uses in its M400 and M4000 products. In the six months ended June 30, 2023, the Company made a final investment of $125,000 to these system upgrades, which were placed into service during the quarter. These additional upgrades of $500,000 are being amortized on a straight-line base over thirty-six (36) months.

Total amortization expense related to all software updates for the three months ended June 30, 2023, and 2022 were $83,333 and $41,667, respectively. Total amortization expense related to all software updates for the six months ended June 30, 2023, and 2022 were $138,889 and $83,333, respectively.

v3.23.2
Accrued Expenses
6 Months Ended
Jun. 30, 2023
Accrued Expenses  
Accrued Expenses

Note 8 – Accrued Expenses

Accrued expenses consisted of the following:

June 30, 

December 31, 

    

2023

    

2022

Accrued Wages and Related Costs

$

478,116

$

843,537

Accrued Professional Services

 

152,400

 

263,800

Accrued Warranty Obligations

 

198,700

 

159,927

Other Accrued Expenses

 

199,961

 

403,275

Total

$

1,029,177

$

1,670,539

The Company has warranty obligations in connection with the sale of certain of its products. The warranty period for its products is generally twelve (12) months. The costs incurred to provide for these warranty obligations are estimated and recorded as an accrued expense at the time of sale. The Company estimates its future warranty costs based upon product-based historical performance rates and related costs to repair.

The changes in the Company’s accrued warranty obligations for the six months ended June 30, 2023, were as follows:

Accrued Warranty Obligations at December 31, 2022

$

159,927

Reductions for Settling Warranties

 

(219,723)

Warranties Issued During Year

 

258,496

Accrued Warranty Obligations at June 30, 2023

$

198,700

v3.23.2
Income Taxes
6 Months Ended
Jun. 30, 2023
Income Taxes  
Income Taxes

Note 9 – Income Taxes

The Company’s effective income tax rate is a combination of federal, state and foreign tax rates and differs from the U.S. statutory rate due to taxes on foreign income, permanent differences including tax-exempt interest, and the resolution of tax uncertainties, offset by a valuation allowance against U.S. deferred income tax assets.

v3.23.2
Capital Stock
6 Months Ended
Jun. 30, 2023
Capital Stock  
Capital Stock

Note 10 – Capital Stock

Preferred stock

The Board of Directors is authorized to establish and designate different series of preferred stock and to fix and determine their voting powers and other rights and terms. A total of 5,000,000 shares of preferred stock with a par value of $0.001 are authorized as of June 30, 2023, and December 31, 2022. Of this total, 49,626 shares are designated as Series A Preferred Stock. There were nil shares of Series A Preferred Stock issued and outstanding on June 30, 2023, and December 31, 2022, respectively.

Common Stock

The Company’s authorized common stock consists of 100,000,000 shares, par value of $0.001. There were 63,898,889 shares issued and 63,319,217 shares outstanding as of June 30, 2023, and 63,783,779 shares issued and 63,319,107 shares outstanding as of December 31, 2022.

In connection with the Atomistic Technology Licenses discussed in Note 6, the Company will, upon certain deliverables and the achievement of milestones contained in the Atomistic Agreements, be committed to pay $2,500,000 and to issue, depending on the Company’s share price within a $13.00 to $8.00 range at the time of their issuance, a minimum of 1,750,000 up to a maximum of 2,874,754 common shares of Vuzix to the stockholders of Atomistic (as a

portion of the consideration for certain shares of Atomistic) which would result in Vuzix owning Series A Preferred shares in Atomistic that could ultimately be converted into ordinary shares of Atomistic and Vuzix ultimately owning 100% of Atomistic. The share issuances by the Company are expected to be issued over the next 6 to 18 months.

Treasury Stock

On March 2, 2022, our Board of Directors approved the Company to repurchase up to an aggregate of $25 million of our common stock by open market or privately negotiated transactions under the Share Buyback Program.  This program was in effect for one year and expired on March 2, 2023. During the three months ended March 31, 2023, the Company repurchased 115,000 shares of our common stock at an average cost of $4.06, before commission of $0.03 per share. As of June 30, 2023, 579,672 shares of our common stock were held in treasury.

v3.23.2
Stock-Based Compensation
6 Months Ended
Jun. 30, 2023
Stock-Based Compensation  
Stock-Based Compensation

Note 11 – Stock-Based Compensation

A summary of stock option activity related to the Company’s standard employee incentive plan (excluding options awarded under the Long-Term Incentive Plan (LTIP) – Note 12) for the six months ended June 30, 2023, is as follows:

Weighted

Average

Number of

Average

Remaining Life

    

Options

    

Exercise Price

    

(years)

Outstanding at December 31, 2022

 

2,805,673

$

7.80

 

7.28

Granted

 

124,000

 

4.80

 

  

Exercised

 

(18,240)

 

1.33

 

  

Expired or Forfeited

 

(36,791)

 

10.64

 

  

Outstanding at June 30, 2023

 

2,874,642

$

7.67

 

6.94

The weighted average remaining contractual term for all options as of June 30, 2023, and December 31, 2022, was 6.94 years and 7.28 years, respectively.

As of June 30, 2023, there were 1,765,244 options that were fully vested and exercisable at a weighted average exercise price of $7.04 per share. The weighted average remaining contractual term of the vested options is 6.1 years.

As of June 30, 2023, there were 1,109,398 unvested options exercisable at a weighted average exercise price of $8.84 per share. The weighted average remaining contractual term of the unvested options is 8.3 years.

The weighted average fair value of option grants was calculated using the Black-Scholes-Merton option pricing method. As of June 30, 2023, the Company had $6,863,003 of unrecognized stock compensation expense, which will be recognized over a weighted average period of 2.2 years.

During the three months ended June 30, 2023, the Company issued 96,525 shares of common stock to its independent board members as part of their annual retainer for services covering the period of July 2023 to June 2024. The fair market value on the date of award of the stock issued was $5.18, resulting in an aggregate fair value of approximately $500,000. The fair market value of these awards is expensed over twelve (12) months, beginning on July 1, 2023.

For the three months ended June 30, 2023, and 2022, the Company recorded total stock-based compensation expense, including stock awards but excluding stock option awards under the Company’s LTIP, of $1,083,064 and $1,222,733, respectively. For the six months ended June 30, 2023, and 2022, the Company recorded total stock-based compensation expense, including stock awards but excluding stock option awards under the Company’s LTIP, of $2,212,630 and $2,573,343, respectively.

v3.23.2
Long-Term Incentive Plan
6 Months Ended
Jun. 30, 2023
Long-Term Incentive Plan  
Long-Term Incentive Plan

Note 12 – Long-Term Incentive Plan

On March 17, 2021, the Company granted options to purchase a total of 5,784,000 shares of common stock to its officers and certain other members of its management team. The options were granted under the Company’s existing 2014 Incentive Stock Plan. The options have an exercise price of $19.00, with 375,000 options vesting immediately and the remaining portion vesting upon the achievement of certain equity market capitalization milestones, and revenue and EBITDA operational milestones. For the three months ended June 30, 2023, and 2022, the Company recorded non-cash stock-based compensation expense of $1,749,687 and $2,658,294, respectively, for options that vested or are probable to vest. For the six months ended June 30, 2023, and 2022, the Company recorded non-cash stock-based compensation expense of $4,287,631 and $5,627,432, respectively, for options that vested or are probable to vest. These expenses are presented in the same financial statement line items in the Statements of Operations as the cash-based compensation expenses for the same employees.

The fair value of option grants was calculated using a Monte Carlo simulation for the equity market capitalization tranches and the Black-Scholes-Merton option pricing method for the operational milestone tranches. As of June 30, 2023, we had $12,922,301 of total unrecognized stock-based compensation expense for the portion of options tied to equity market capitalization milestones and the portion of options tied to operational milestones that were considered probable of achievement, all of which will be recognized over a service period of up to three to four years. The probabilities of the milestone achievements are subject to catch-up adjustments in each instance where an equity market capitalization milestone is achieved or when an operational milestone becomes probable to be achieved or is achieved. Compensation costs could be reversed in subsequent periods if an awardee leaves the Company prior to the expiration of the option life for market capitalization milestone or performance award vesting of a performance award no longer determined to be probable. If such milestones are achieved earlier in their expected service periods, the remaining unrecognized compensation expense related to that particular milestone would be accelerated and recognized in full during the period where that achievement is affirmed by the Board of Directors. As of June 30, 2023, and going forward, should all of the operational milestones which are currently not yet deemed probable of achievement become probable of achievement or are achieved, then the Company could ultimately recognize up to an additional $34.1 million in non-cash stock-based compensation expense at such time.

The unvested remaining equity market and operational milestones under the LTIP with their total related option grants and criteria achievement weightings of the options available for meeting a target are shown in the following table. Of the total 5,409,000 unvested options outstanding as of June 30, 2023, there are 2,704,500 options unvested for the achievement of Equity Market Capitalization targets, 1,893,150 unvested options for the achievement of annual Revenue targets, and 811,350 unvested options for the achievement of annual EBITDA Margins Before Non-Cash Charges targets.

Award Potential

Criteria Achievement Weighting

50% of Options Available

35% of Options Available

15% of Options Available

Options Available
(Subject to Vesting)

Equity Market
Capitalization
Target

Last Twelve Months Revenue
Target

Last Twelve Months EBITDA Target

686,000

$ 2,000,000,000

$ 25,000,000

0.0%

686,000

3,000,000,000

50,000,000

2.0%

686,000

4,000,000,000

100,000,000

4.0%

686,000

5,000,000,000

200,000,000

6.0%

586,000

6,000,000,000

300,000,000

8.0%

586,000

7,000,000,000

450,000,000

10.0%

561,000

8,000,000,000

675,000,000

12.0%

491,000

9,000,000,000

1,000,000,000

14.0%

441,000

10,000,000,000

1,500,000,000

16.0%

5,409,000

v3.23.2
Litigation
6 Months Ended
Jun. 30, 2023
Litigation  
Litigation

Note 13 – Litigation

We are not currently involved in any actual or pending legal proceedings or litigation that we consider to be material, and we are not aware of any such material proceedings contemplated by or against us or involving our property.

v3.23.2
Right-of-Use Assets and Liabilities
6 Months Ended
Jun. 30, 2023
Right-of-Use Assets and Liabilities  
Right-of-Use Assets and Liabilities

Note 14 – Right-of-Use Assets and Liabilities

Future lease payments under operating leases as of June 30, 2023 were as follows:

2023 (6 months remaining)

$

348,826

2024

 

191,120

2025

 

132,982

Total Future Lease Payments

 

672,928

Less: Imputed Interest

 

(44,797)

Total Lease Liability Balance

$

628,131

Operating lease costs under the operating leases totaled $207,352 and $163,277 for the three months ended June 30, 2023, and 2022, respectively. Operating lease costs under the operating leases totaled $410,691 and $325,642 for the six months ended June 30, 2023, and 2022, respectively.

As of June 30, 2023, the weighted average discount rate was 7.1% and the weighted average remaining lease term was 1.5 years.

v3.23.2
Basis of Presentation (Policies)
6 Months Ended
Jun. 30, 2023
Basis of Presentation  
Basis of Presentation

The accompanying unaudited consolidated financial statements of Vuzix Corporation (“the Company” or “Vuzix”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, the unaudited consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Certain re-classifications have been made to prior comparable periods to conform with current reporting impacting Costs of Sales, Gross Profit and Depreciation and Amortization. The results of the Company’s operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results of the Company’s operations for the full fiscal year or any other period.

The accompanying interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto of the Company as of and for the year ended December 31, 2022, as reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2023.

Reclassification of Prior Year Presentation

Re-classification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year’s presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Operations for the three and six months ended June 30, 2022, to reclassify depreciation expense related to our manufacturing operations from the amounts of reported depreciation and amortization expenses originally included in Operating Expenses. This change in classification does not affect previously reported Net Loss or reported Cash Flows Used in Operating Activities in the Consolidated Statements of Cash Flows or Consolidated Balance Sheets. The below table is a summary of the impact of these re-classifications:

For the Three Months Ended June 30, 2022

For the Six Months Ended June, 2022

As Previously

As Previously

Condensed Statement of Operations

    

Presented

    

Re-classification

    

Revised

    

Presented

    

Re-classification

    

Revised

Total Sales

$

3,007,758

$

$

3,007,758

$

5,510,810

$

$

5,510,810

Cost of Sales - Products Sold

2,522,674

(70,784)

2,451,890

4,386,371

(130,883)

4,255,488

Cost of Sales - Depreciation and Amortization

231,163

231,163

454,949

454,949

Cost of Sales - Engineering Services

59,296

59,296

59,296

59,296

Gross Profit

425,788

160,379

265,409

1,065,143

324,066

741,077

Operating Expenses:

Research and Development

2,996,144

2,996,144

6,099,588

6,099,588

Selling and Marketing

1,850,595

1,850,595

3,914,584

3,914,584

General and Administrative

5,039,949

5,039,949

10,453,228

10,453,228

Depreciation and Amortization

540,081

(160,379)

379,702

963,012

(324,066)

638,946

Impairment of Patents and Trademarks

49,602

49,602

Total Operating Expenses

10,426,769

(160,379)

10,266,390

21,480,014

(324,066)

21,155,948

Loss From Operations

 

(10,000,981)

 

 

(10,000,981)

 

(20,414,871)

 

 

(20,414,871)

Total Other Expense, Net

(20,687)

(20,687)

(112,797)

(112,797)

Net Loss

$

(10,021,668)

$

$

(10,021,668)

$

(20,527,668)

$

$

(20,527,668)

Customer Concentrations

Customer Concentrations

For the three months ended June 30, 2023, one customer represented 75% of total product revenue. For the three months ended June 30, 2022, one customer represented 45% of total product revenue.

For the six months ended June 30, 2023, two customers represented 40% and 35% of total product revenue. For the six months ended June 30, 2022, one customer represented 24% of total product revenue.

As of June 30, 2023, two customers represented 58% and 23% of accounts receivable. As of December 31, 2022, one customer represented 26% of accounts receivable.

Treasury Stock

Treasury Stock

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains and losses on the subsequent re-issuance of shares will be credited or charged to paid-in capital in excess of par value using the average-cost method.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). ASU 2016-13 provides for a new impairment model which requires measurement and recognition of expected credit losses for most financial assets and certain other instruments, including but not limited to, accounts receivable. The Company adopted ASU 2016-13 effective on January 1, 2023. The adoption of this standard did not have a material impact on our consolidated financial statements.

v3.23.2
Basis of Presentation (Tables)
6 Months Ended
Jun. 30, 2023
Basis of Presentation  
Reclassification of prior year presentation

For the Three Months Ended June 30, 2022

For the Six Months Ended June, 2022

As Previously

As Previously

Condensed Statement of Operations

    

Presented

    

Re-classification

    

Revised

    

Presented

    

Re-classification

    

Revised

Total Sales

$

3,007,758

$

$

3,007,758

$

5,510,810

$

$

5,510,810

Cost of Sales - Products Sold

2,522,674

(70,784)

2,451,890

4,386,371

(130,883)

4,255,488

Cost of Sales - Depreciation and Amortization

231,163

231,163

454,949

454,949

Cost of Sales - Engineering Services

59,296

59,296

59,296

59,296

Gross Profit

425,788

160,379

265,409

1,065,143

324,066

741,077

Operating Expenses:

Research and Development

2,996,144

2,996,144

6,099,588

6,099,588

Selling and Marketing

1,850,595

1,850,595

3,914,584

3,914,584

General and Administrative

5,039,949

5,039,949

10,453,228

10,453,228

Depreciation and Amortization

540,081

(160,379)

379,702

963,012

(324,066)

638,946

Impairment of Patents and Trademarks

49,602

49,602

Total Operating Expenses

10,426,769

(160,379)

10,266,390

21,480,014

(324,066)

21,155,948

Loss From Operations

 

(10,000,981)

 

 

(10,000,981)

 

(20,414,871)

 

 

(20,414,871)

Total Other Expense, Net

(20,687)

(20,687)

(112,797)

(112,797)

Net Loss

$

(10,021,668)

$

$

(10,021,668)

$

(20,527,668)

$

$

(20,527,668)

v3.23.2
Revenue Recognition and Contracts with Customers (Tables)
6 Months Ended
Jun. 30, 2023
Revenue Recognition and Contracts with Customers  
Schedule of company's total revenue by major product lines

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2023

    

2022

    

2023

    

2022

Revenues

 

  

 

  

 

  

 

  

Products Sales

$

4,425,162

$

2,898,892

$

8,616,523

$

5,401,944

Engineering Services

 

265,673

 

108,866

 

265,673

 

108,866

Total Revenue

$

4,690,835

$

3,007,758

$

8,882,196

$

5,510,810

Schedule of company's net sales by revenue recognition method as a percentage of total net sales

    

% of Total Net Sales

2023

 

2022

 

Point-in-Time

 

97%

%

98%

%

Over Time – Input Method

 

3%

%

2%

%

Total

 

100%

%

100%

%

v3.23.2
Inventories, Net (Tables)
6 Months Ended
Jun. 30, 2023
Inventories, Net  
Schedule of Inventories

June 30, 

December 31, 

    

2023

    

2022

Purchased Parts and Components

$

9,780,977

$

10,399,527

Work-in-Process

 

518,460

 

344,242

Finished Goods

 

2,468,476

 

1,941,689

Less: Reserve for Obsolescence

 

(1,897,747)

 

(1,417,489)

Inventories, Net

$

10,870,166

$

11,267,969

v3.23.2
Fixed Assets (Tables)
6 Months Ended
Jun. 30, 2023
Fixed Assets  
Schedule of Fixed Assets

June 30, 

December 31, 

    

2023

    

2022

Tooling and Manufacturing Equipment

$

8,866,022

$

6,065,445

Leaseholds

 

1,472,898

 

826,329

Computers and Purchased Software

 

789,036

 

760,256

Furniture and Equipment

 

2,513,575

 

2,487,650

 

13,641,531

 

10,139,680

Less: Accumulated Depreciation

 

(6,827,526)

 

(6,261,175)

Fixed Assets, Net

$

6,814,005

$

3,878,505

v3.23.2
Technology Licenses, Net (Tables)
6 Months Ended
Jun. 30, 2023
Licenses [Member]  
Schedule of Finite-Lived Intangible Assets

June 30, 

December 31, 

    

2023

    

2022

Licenses

$

32,443,356

$

2,443,356

Additions

 

 

30,000,000

Less: Accumulated Amortization

 

(3,938,486)

 

(2,284,667)

Licenses, Net

$

28,504,870

$

30,158,689

v3.23.2
Other Assets (Tables)
6 Months Ended
Jun. 30, 2023
Other Assets  
Schedule of other assets

June 30,

December 31, 

    

2023

    

2022

Private Corporation Investments

$

450,000

$

450,000

Additions

200,000

Total Private Corporation Investments (at cost)

650,000

450,000

Software Development Costs

875,000

750,000

Additions

125,000

125,000

Less: Accumulated Amortization

(513,889)

(375,000)

Software Development Costs, Net

486,111

500,000

Unamortized Common Stock Expense included in Long-Term Prepaid Expenses

513,021

631,143

Total Other Assets

$

1,649,132

$

1,581,143

v3.23.2
Accrued Expenses (Tables)
6 Months Ended
Jun. 30, 2023
Accrued Expenses  
Schedule of Accrued Expenses

June 30, 

December 31, 

    

2023

    

2022

Accrued Wages and Related Costs

$

478,116

$

843,537

Accrued Professional Services

 

152,400

 

263,800

Accrued Warranty Obligations

 

198,700

 

159,927

Other Accrued Expenses

 

199,961

 

403,275

Total

$

1,029,177

$

1,670,539

Schedule of changes in accrued warranty obligations

Accrued Warranty Obligations at December 31, 2022

$

159,927

Reductions for Settling Warranties

 

(219,723)

Warranties Issued During Year

 

258,496

Accrued Warranty Obligations at June 30, 2023

$

198,700

v3.23.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2023
Stock-Based Compensation  
Schedule of Summary of Stock Option Activity

Weighted

Average

Number of

Average

Remaining Life

    

Options

    

Exercise Price

    

(years)

Outstanding at December 31, 2022

 

2,805,673

$

7.80

 

7.28

Granted

 

124,000

 

4.80

 

  

Exercised

 

(18,240)

 

1.33

 

  

Expired or Forfeited

 

(36,791)

 

10.64

 

  

Outstanding at June 30, 2023

 

2,874,642

$

7.67

 

6.94

v3.23.2
Long-Term Incentive Plan (Tables)
6 Months Ended
Jun. 30, 2023
Long-Term Incentive Plan  
Schedule of equity market and operational milestone under the long term

Award Potential

Criteria Achievement Weighting

50% of Options Available

35% of Options Available

15% of Options Available

Options Available
(Subject to Vesting)

Equity Market
Capitalization
Target

Last Twelve Months Revenue
Target

Last Twelve Months EBITDA Target

686,000

$ 2,000,000,000

$ 25,000,000

0.0%

686,000

3,000,000,000

50,000,000

2.0%

686,000

4,000,000,000

100,000,000

4.0%

686,000

5,000,000,000

200,000,000

6.0%

586,000

6,000,000,000

300,000,000

8.0%

586,000

7,000,000,000

450,000,000

10.0%

561,000

8,000,000,000

675,000,000

12.0%

491,000

9,000,000,000

1,000,000,000

14.0%

441,000

10,000,000,000

1,500,000,000

16.0%

5,409,000

v3.23.2
Right-of-Use Assets and Liabilities (Tables)
6 Months Ended
Jun. 30, 2023
Right-of-Use Assets and Liabilities  
Schedule of Future lease payments under operating leases

2023 (6 months remaining)

$

348,826

2024

 

191,120

2025

 

132,982

Total Future Lease Payments

 

672,928

Less: Imputed Interest

 

(44,797)

Total Lease Liability Balance

$

628,131

v3.23.2
Basis of Presentation - Reclassification of results of operations (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Total Sales $ 4,690,835 $ 3,007,758 $ 8,882,196 $ 5,510,810
Cost of Sales - Depreciation and Amortization 257,939 231,163 490,855 454,949
Gross Profit 972,386 265,409 1,848,392 741,077
Operating Expenses:        
Research and Development 2,836,552 2,996,144 5,906,349 6,099,588
Selling and Marketing 2,509,922 1,850,595 5,049,581 3,914,584
General and Administrative 4,260,322 5,039,949 9,392,146 10,453,228
Depreciation and Amortization 973,222 379,702 1,937,487 638,946
Impairment of Patents and Trademarks     17,666 49,602
Total Operating Expenses 10,580,018 10,266,390 22,303,229 21,155,948
Loss From Operations (9,607,632) (10,000,981) (20,454,837) (20,414,871)
Total Other Expense, Net 562,712 (20,687) 1,169,334 (112,797)
Net loss (9,044,920) (10,021,668) (19,285,503) (20,527,668)
Previously Reported [Member]        
Total Sales   3,007,758   5,510,810
Gross Profit   425,788   1,065,143
Operating Expenses:        
Research and Development   2,996,144   6,099,588
Selling and Marketing   1,850,595   3,914,584
General and Administrative   5,039,949   10,453,228
Depreciation and Amortization   540,081   963,012
Impairment of Patents and Trademarks       49,602
Total Operating Expenses   10,426,769   21,480,014
Loss From Operations   (10,000,981)   (20,414,871)
Total Other Expense, Net   (20,687)   (112,797)
Net loss   (10,021,668)   (20,527,668)
Revision of Prior Period, Error Correction, Adjustment [Member]        
Cost of Sales - Depreciation and Amortization   231,163   454,949
Gross Profit   160,379   324,066
Operating Expenses:        
Depreciation and Amortization   (160,379)   (324,066)
Total Operating Expenses   (160,379)   (324,066)
Revision of Prior Period, As Restated [Member]        
Total Sales   3,007,758   5,510,810
Cost of Sales - Depreciation and Amortization   231,163   454,949
Gross Profit   265,409   741,077
Operating Expenses:        
Research and Development   2,996,144   6,099,588
Selling and Marketing   1,850,595   3,914,584
General and Administrative   5,039,949   10,453,228
Depreciation and Amortization   379,702   638,946
Impairment of Patents and Trademarks       49,602
Total Operating Expenses   10,266,390   21,155,948
Loss From Operations   (10,000,981)   (20,414,871)
Total Other Expense, Net   (20,687)   (112,797)
Net loss   (10,021,668)   (20,527,668)
Sales of Products        
Total Sales 4,425,162 2,898,892 8,616,523 5,401,944
Cost of Sales 3,303,979 2,451,890 6,386,418 4,255,488
Sales of Products | Previously Reported [Member]        
Cost of Sales   2,522,674   4,386,371
Sales of Products | Revision of Prior Period, Error Correction, Adjustment [Member]        
Cost of Sales   (70,784)   (130,883)
Sales of Products | Revision of Prior Period, As Restated [Member]        
Cost of Sales   2,451,890   4,255,488
Sales of Engineering Services        
Total Sales 265,673 108,866 265,673 108,866
Cost of Sales $ 156,531 59,296 $ 156,531 59,296
Sales of Engineering Services | Previously Reported [Member]        
Cost of Sales   59,296   59,296
Sales of Engineering Services | Revision of Prior Period, As Restated [Member]        
Cost of Sales   $ 59,296   $ 59,296
v3.23.2
Basis of Presentation (Details) - customer
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Total revenues | Sales of Products          
Number of customers 1 1 2 1  
Accounts Receivable          
Number of customers     2   1
One customer | Total revenues | Sales of Products | Customer Concentration Risk          
Concentration Risk, Percentage 75.00% 45.00% 40.00% 24.00%  
One customer | Accounts Receivable | Customer Concentration Risk          
Concentration Risk, Percentage     58.00%   26.00%
Two customers | Total revenues | Sales of Products | Customer Concentration Risk          
Concentration Risk, Percentage     35.00%    
Two customers | Accounts Receivable | Customer Concentration Risk          
Concentration Risk, Percentage     23.00%    
v3.23.2
Revenue Recognition and Contracts with Customers - Company's total revenue by major product lines (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
product
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
product
Jun. 30, 2022
USD ($)
Number of major product lines | product 2   2  
Revenue $ 4,690,835 $ 3,007,758 $ 8,882,196 $ 5,510,810
Products Sales        
Revenue 4,425,162 2,898,892 8,616,523 5,401,944
Engineering Services        
Revenue $ 265,673 $ 108,866 $ 265,673 $ 108,866
v3.23.2
Revenue Recognition and Contracts with Customers - Company's net sales as a percentage (Details)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Revenue Performance Obligation Percentage 100.00% 100.00%
Point-in-Time    
Revenue Performance Obligation Percentage 97.00% 98.00%
Over Time - Input Method    
Revenue Performance Obligation Percentage 3.00% 2.00%
v3.23.2
Revenue Recognition and Contracts with Customers - Additional Information (Details) - USD ($)
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Standard product warranty term 12 months  
Revenue, remaining performance obligations $ 80,000  
Revenue, performance obligation, total transaction price 800,000  
Accrued Revenues in Excess of Billings $ 309,762 $ 269,129
OEM products and waveguide sales    
Standard product warranty term 18 months  
v3.23.2
Loss Per Share - Additional Information (Details) - shares
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Loss Per Share    
Anti-dilutive shares 8,658,642 8,528,668
v3.23.2
Inventories, Net - Components of Inventories (Detail) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Inventories, Net    
Purchased Parts and Components $ 9,780,977 $ 10,399,527
Work-in-Process 518,460 344,242
Finished Goods 2,468,476 1,941,689
Less: Reserve for Obsolescence (1,897,747) (1,417,489)
Inventories, Net $ 10,870,166 $ 11,267,969
v3.23.2
Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Fixed Assets, Gross $ 13,641,531 $ 10,139,680
Less: Accumulated Depreciation (6,827,526) (6,261,175)
Fixed Assets, Net 6,814,005 3,878,505
Tooling and Manufacturing Equipment    
Property, Plant and Equipment [Line Items]    
Fixed Assets, Gross 8,866,022 6,065,445
Leaseholds    
Property, Plant and Equipment [Line Items]    
Fixed Assets, Gross 1,472,898 826,329
Computers and Purchased Software    
Property, Plant and Equipment [Line Items]    
Fixed Assets, Gross 789,036 760,256
Furniture and Equipment    
Property, Plant and Equipment [Line Items]    
Fixed Assets, Gross $ 2,513,575 $ 2,487,650
v3.23.2
Fixed Assets - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]          
Final investment for system upgradation     $ 2,774,513 $ 3,504,931  
Depreciation expense not included in Cost of Sales $ 111,934 $ 111,943 214,385 $ 229,029  
Atomistic SAS          
Property, Plant and Equipment [Line Items]          
Exclusive license agreement, total value         $ 30,000,000
Tooling and Manufacturing Equipment          
Property, Plant and Equipment [Line Items]          
Final investment for system upgradation     $ 2,774,513    
v3.23.2
Technology Licenses, Net (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Licenses Net [Line Items]    
Licenses, Net $ 28,504,870 $ 30,158,689
Licensing agreements    
Licenses Net [Line Items]    
Licenses 32,443,356 2,443,356
Additions   30,000,000
Less: Accumulated Amortization (3,938,486) (2,284,667)
Licenses, Net $ 28,504,870 $ 30,158,689
v3.23.2
Technology Licenses, Net - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Atomistic SAS          
Licenses Net [Line Items]          
Exclusive license agreement, total value         $ 30,000,000
Duration of time to pay the commitment fee     6 months    
Licensing agreements          
Licenses Net [Line Items]          
Amortization expense $ 826,984 $ 244,201 $ 1,653,868 $ 300,901  
Licensing agreements | Atomistic SAS          
Licenses Net [Line Items]          
Licensing fees commitment $ 3,500,000   $ 3,500,000    
Amortization Period (Years) 10 years   10 years    
v3.23.2
Other Assets (Details) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Private Corporation Investments $ 450,000 $ 450,000
Additions 200,000  
Total Private Corporation Investments (at cost) 650,000 450,000
Additions 6,814,005 3,878,505
Unamortized Common Stock Expense included in Long-Term Prepaid Expenses 513,021 631,143
Total Other Assets 1,649,132 1,581,143
Software Development    
Software Development Costs 875,000 750,000
Additions 125,000 125,000
Less: Accumulated Amortization (513,889) (375,000)
Software Development Costs, Net $ 486,111 $ 500,000
v3.23.2
Other Assets - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 21 Months Ended
Oct. 31, 2021
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2020
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Other assets [Line Items]                      
Fixed Assets, Net   $ 6,814,005       $ 6,814,005     $ 6,814,005 $ 3,878,505  
Investment for system upgradation           340,507 $ 272,686        
Capitalized Software Development Costs                      
Other assets [Line Items]                      
Amortization of Intangible Assets   83,333   $ 41,667   138,889 $ 83,333        
Software Development                      
Other assets [Line Items]                      
Fixed Assets, Net   $ 125,000       125,000     125,000 $ 125,000  
Useful life               36 months      
Investment for system upgradation $ 250,000   $ 125,000   $ 125,000 $ 125,000   $ 500,000 $ 500,000    
Amortization period (in months)   36 months       36 months     36 months    
Private Corporation                      
Other assets [Line Items]                      
Purchase price   $ 100,000       $ 100,000     $ 100,000   $ 200,000
Ownership interest   2.00%       2.00%     2.00%   3.00%
UK Based Public Company                      
Other assets [Line Items]                      
Purchase price   $ 100,000       $ 100,000     $ 100,000    
UK Based Public Company | Maximum                      
Other assets [Line Items]                      
Ownership interest   1.00%       1.00%     1.00%    
v3.23.2
Accrued Expenses - Components of Accrued Expenses (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Accrued Expenses    
Accrued Wages and Related Costs $ 478,116 $ 843,537
Accrued Professional Services 152,400 263,800
Accrued Warranty Obligations 198,700 159,927
Other Accrued Expenses 199,961 403,275
Total $ 1,029,177 $ 1,670,539
v3.23.2
Accrued Expenses - Additional Information (Details)
6 Months Ended
Jun. 30, 2023
Accrued Expenses  
Standard product warranty term 12 months
v3.23.2
Accrued Expenses - Changes in Accrued Warranty Obligations (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
Accrued Expenses  
Accrued Warranty Obligations, beginning of period $ 159,927
Reductions for Settling Warranties (219,723)
Warranties Issued During Year 258,496
Accrued Warranty Obligations, end of period $ 198,700
v3.23.2
Capital Stock (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 02, 2022
Mar. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Preferred Stock, Shares Authorized     5,000,000 5,000,000
Preferred Stock, Par Value     $ 0.001 $ 0.001
Common Stock, Shares Authorized     100,000,000 100,000,000
Common Stock, Par Value     $ 0.001 $ 0.001
Common Stock, Shares Issued     63,898,889 63,783,779
Common Stock, Shares Outstanding     63,319,217 63,319,107
Aggregate value of shares authorized $ 25,000,000      
Share repurchase program term 1 year      
Purchases of Treasury Stock (in Shares)   115,000    
Average cost   $ 4.06    
Commission cost per share   $ 0.03    
Common shares held in treasury     579,672 464,672
Atomistic SAS        
Ownership percent     100.00%  
Atomistic agreement        
Amount committed to pay upon the achievement or waiver of performance milestones     $ 2,500,000  
Minimum | Atomistic agreement        
Issuance of shares, performance milestones (in shares)     1,750,000  
Period of time to issue per agreement     6 months  
Market share price     $ 8.00  
Maximum | Atomistic agreement        
Issuance of shares, performance milestones (in shares)     2,874,754  
Period of time to issue per agreement     18 months  
Market share price     $ 13.00  
Series A Preferred Stock        
Preferred Stock, Shares Authorized     49,626 49,626
Preferred Stock, Shares Issued     0 0
Preferred Stock, Shares Outstanding     0 0
v3.23.2
Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Weighted Average Remaining Life (Years)    
Options Outstanding, Weighted Average Remaining Life (Years) 6 years 11 months 8 days 7 years 3 months 10 days
Employee Stock Option [Member]    
Number of Options    
Outstanding, Beginning Balance 2,805,673  
Granted 124,000  
Exercised (18,240)  
Expired or Forfeited (36,791)  
Outstanding, Ending Balance 2,874,642 2,805,673
Weighted Average Exercise Price    
Outstanding, Beginning Balance $ 7.80  
Granted 4.80  
Exercised 1.33  
Expired or Forfeited 10.64  
Outstanding, Ending Balance $ 7.67 $ 7.80
v3.23.2
Stock-Based Compensation - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Stock-Based Compensation Plans        
Exercisable Options Outstanding Shares 1,765,244   1,765,244  
Weighted average exercise price per share, Exercisable $ 7.04   $ 7.04  
Weighted average remaining contractual term on vested options     6 years 1 month 6 days  
Unvested Options Outstanding, Shares 1,109,398   1,109,398  
Unvested Options Outstanding, Weighted average exercise price     $ 8.84  
Unvested Options Outstanding Weighted average remaining life (years)     8 years 3 months 18 days  
Unrecognized stock compensation expense $ 6,863,003   $ 6,863,003  
Weighted average recognition period     2 years 2 months 12 days  
Share-Based compensation excludes the long term incentive plan expense $ 1,083,064 $ 1,222,733 $ 2,212,630 $ 2,573,343
Board of directors and management members        
Stock-Based Compensation Plans        
Stock award issued 96,525      
Weighted average fair value per share $ 5.18      
Aggregate fair value $ 500,000      
v3.23.2
Long-Term Incentive Plan (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 17, 2021
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Long-term Incentive Plan            
Exercise price   $ 7.04   $ 7.04    
Share-based Compensation       $ 6,500,261 $ 8,200,774  
Options available in equity market and operational milestone       5,409,000    
Unrecognized stock compensation expense   $ 6,863,003   $ 6,863,003    
Weighted average recognition period       2 years 2 months 12 days    
Equity Market Capitalization Targets            
Long-term Incentive Plan            
Options available in equity market and operational milestone       2,704,500    
Annual Revenue Targets            
Long-term Incentive Plan            
Options available in equity market and operational milestone       1,893,150    
Annual EBITDA Margins Before Non-Cash Charges Targets            
Long-term Incentive Plan            
Options available in equity market and operational milestone       811,350    
Employee Stock Option [Member] | Long-term Incentive Plan 2021            
Long-term Incentive Plan            
Granted 5,784,000          
Exercise price $ 19.00          
Share-based Compensation   1,749,687 $ 2,658,294 $ 4,287,631 $ 5,627,432  
Employee Stock Option [Member] | Vest immediately | Long-term Incentive Plan 2021            
Long-term Incentive Plan            
Shares vesting 375,000          
Stock options tied to equity market capitalization milestone            
Long-term Incentive Plan            
Amount of threshold additional stock based compensation expense           $ 34,100,000
Unrecognized stock compensation expense   $ 12,922,301   $ 12,922,301    
Stock options tied to equity market capitalization milestone | Minimum            
Long-term Incentive Plan            
Weighted average recognition period       3 years    
Stock options tied to equity market capitalization milestone | Maximum            
Long-term Incentive Plan            
Weighted average recognition period       4 years    
v3.23.2
Long-Term Incentive Plan - LTIP (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
shares
Long-term Incentive Plan  
Percentage of weightage for equity market capitalization target 50.00%
Percentage of weightage for last twelve months revenue target 35.00%
Percentage of weightage for last twelve months EBITDA margin before non-cash charges 15.00%
Options available in equity market and operational milestone | shares 5,409,000
Stock option tied to equity market and operational milestones  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 5,409,000
Equity market and operational milestone one  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 686,000
Amount of equity market capitalization target $ 2,000,000,000
Amount of last twelve months revenue target under the equity market and operational milestone under LTIP $ 25,000,000
Percentage of last twelve months EBITDA margin before non-cash charges target 0.00%
Equity market and operational milestone two  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 686,000
Amount of equity market capitalization target $ 3,000,000,000
Amount of last twelve months revenue target under the equity market and operational milestone under LTIP $ 50,000,000
Percentage of last twelve months EBITDA margin before non-cash charges target 2.00%
Equity market and operational milestone three  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 686,000
Amount of equity market capitalization target $ 4,000,000,000
Amount of last twelve months revenue target under the equity market and operational milestone under LTIP $ 100,000,000
Percentage of last twelve months EBITDA margin before non-cash charges target 4.00%
Equity market and operational milestone four  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 686,000
Amount of equity market capitalization target $ 5,000,000,000
Amount of last twelve months revenue target under the equity market and operational milestone under LTIP $ 200,000,000
Percentage of last twelve months EBITDA margin before non-cash charges target 6.00%
Equity market and operational milestone five  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 586,000
Amount of equity market capitalization target $ 6,000,000,000
Amount of last twelve months revenue target under the equity market and operational milestone under LTIP $ 300,000,000
Percentage of last twelve months EBITDA margin before non-cash charges target 8.00%
Equity market and operational milestone six  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 586,000
Amount of equity market capitalization target $ 7,000,000,000
Amount of last twelve months revenue target under the equity market and operational milestone under LTIP $ 450,000,000
Percentage of last twelve months EBITDA margin before non-cash charges target 10.00%
Equity market and operational milestone seven  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 561,000
Amount of equity market capitalization target $ 8,000,000,000
Amount of last twelve months revenue target under the equity market and operational milestone under LTIP $ 675,000,000
Percentage of last twelve months EBITDA margin before non-cash charges target 12.00%
Equity market and operational milestone eight  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 491,000
Amount of equity market capitalization target $ 9,000,000,000
Amount of last twelve months revenue target under the equity market and operational milestone under LTIP $ 1,000,000,000
Percentage of last twelve months EBITDA margin before non-cash charges target 14.00%
Equity market and operational milestone nine  
Long-term Incentive Plan  
Options available in equity market and operational milestone | shares 441,000
Amount of equity market capitalization target $ 10,000,000,000
Amount of last twelve months revenue target under the equity market and operational milestone under LTIP $ 1,500,000,000
Percentage of last twelve months EBITDA margin before non-cash charges target 16.00%
v3.23.2
Right-of-Use Assets and Liabilities - Operating Leases (Details)
Jun. 30, 2023
USD ($)
Right-of-Use Assets and Liabilities  
2023 (6 months remaining) $ 348,826
2024 191,120
2025 132,982
Total Future Lease Payments 672,928
Less: Imputed Interest (44,797)
Total Lease Liability Balance $ 628,131
v3.23.2
Right-of-Use Assets and Liabilities - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Right-of-Use Assets and Liabilities        
Operating lease costs $ 207,352 $ 163,277 $ 410,691 $ 325,642
Weighted average discount rate 7.10%   7.10%  
Weighted average remaining term 1 year 6 months   1 year 6 months  
v3.23.2
Pay vs Performance Disclosure - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Pay vs Performance Disclosure        
Net Income (Loss) $ (9,044,920) $ (10,021,668) $ (19,285,503) $ (20,527,668)
v3.23.2
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false

Vuzix (NASDAQ:VUZI)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Vuzix Charts.
Vuzix (NASDAQ:VUZI)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Vuzix Charts.